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Obesity is associated with a high risk of incidence of, and mortality for, 
postmenopausal breast cancer. Despite this well-established link, the molecular and 
mechanistic basis of the obesity and breast cancer association still remains unclear. 
In obesity research, genetic variation due to copy number differences has become 
increasingly popular. The salivary amylase gene, AMY1, is well-known for its 
extensive copy number variation (CNV) in the human genome and has previously 
been correlated with a genetic predisposition toward obesity; however, research 
surrounding this association is controversial. Despite an established relationship 
between obesity and breast cancer risk, the recently reported genetic association 
between AMY1 CNV and obesity has not yet been examined in normal and obese 
breast cancer patients. Furthermore, gene expression changes in breast tumours from 
obese women remain poorly characterised. We hypothesise that obese breast cancer 
patients are associated with (1) low AMY1 copy number and (2) differential 
expression of candidate genes in the breast tumour. 
This study included 55 post-menopausal breast cancer patients from The Cancer 
Society Tissue Bank, with a BMI (body mass index)> 30 (obese; n=28) or BMI < 25 
(healthy; n=27). Quantitative PCR (qPCR) assessment of germline AMY1 copy 
number status from blood showed that obese breast cancer patients have a lower 
average copy number of AMY1 compared to normal weight patients. Examining 
breast tumour expression profiles of obese and non-obese patients from two 
published studies, identified four candidate genes (GRIA2, DUSP4, NR2F1, and 
ADH1B) shared between both studies. Analysis of gene expression data from The 
Cancer Genome Atlas (TCGA) indicated that these four genes are differentially 
expressed within clinically relevant breast tumour subtypes characterised by 
oestrogen receptor, progesterone receptor and HER2 status. qPCR analysis of each 
candidate gene within our study cohort showed that the average expression of 
GRIA2, DUSP4, NR2F1 and ADH1B was lower in obese compared to healthy breast 
tumours, but these results were not statistically significant. My study indicated that 
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BMI may be associated with lower germline copy number of AMY1 in post-
menopausal breast cancer patients; however, further work with a larger cohort is 
needed to establish if GRIA2, DUSP4, NR2F1 and ADH1B are associated with 
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1 Introduction  
The prevalence of obesity is increasing worldwide at an alarming rate(1). Increased 
weight gain and obesity are correlated with a number of adverse health effects 
including increased risk of developing a number of different cancers(2). Obesity is 
associated with an increased risk and reduced survival rate of breast cancer in women 
worldwide, particularly in post-menopausal women(3, 4). Despite the well-established 
association between obesity and increased risk of breast cancer, the precise nature in 
which obesity influences breast tumourigenesis still remains relatively unclear.  
Differences in the sequences of an individual’s genome is what contributes to our 
overall uniqueness. Any genomic variations such as large duplications or deletions (ie. 
copy number variation (CNV)) can influence our traits, and cause susceptibility to 
diseases such as obesity. Copy number variants are large structural and highly heritable 
germline variations extensive throughout the human genome (Figure 1.1), yet, non-
recurrent de novo alterations can also cause the formation of unique germline CNV(5). 
Research has confirmed that AMY1 CNV, an extensively studied copy number variant 
in the human genome(6), has evolved as a response to strong positive selection imposed 
by starch intake in the human diet(7). The AMY1 gene is responsible for producing the 
salivary amylase protein active at the start of the human digestion process, breaking 
down large starch molecules into maltose as preparation for further catalysis in the 
stomach. The copy number of AMY1 has recently been linked to a predisposition to 
obesity in which fewer copies of AMY1 is a risk factor for the accumulation of excess 
fat mass(8). Despite the already well supported link between obesity and breast cancer 
risk, the newly established genetic association between AMY1 CNV and increased 
weight gain has not yet been examined in normal and obese breast cancer patients.  
Therefore, this review will examine the potential impact that AMY1 CNV may have on 
risk of breast cancer incidence, by initially providing an overview of obesity genetics, 
followed by examination of the obesity-breast cancer relationship and lastly assessing 




Figure 1.1 Gene showing copy number variation. Copy number variation can be in the form of 




1.1.1 Obesity Epidemic  
Obesity is a medical condition defined as the accumulation of excess fat mass to a point 
of significant increase in adverse health risks associated with the gain in weight(9). The 
rising prevalence of obesity worldwide has given rise to the current term “obesity 
epidemic”(2, 10, 11). In 2012 the World Health Organisation (WHO) calculated the 
prevalence of obesity worldwide to be 500 million, and by 2015 the number of cases 
was predicted to have increased to 700 million(9). Obesity related literature presents 
confirmation that the incidence of obesity is increasing worldwide in both developing 
and developed countries and for people of all ages(1, 10, 12). Generally the obesity 
epidemic is credited to an imbalance between energy consumption, energy expenditure 



























consistent positive energy balance, in that dietary intake outweighs the energy output 
through exercise and metabolic activities(2, 10, 13).  
Clinically a BMI (body mass index: weight in kilograms divided by the square of 
height in metres) above 30, categorises an individual obese(9). BMI is a universal and 
efficient tool for measuring obesity(14).  
 
1.1.2 Obesity and Predictive Ability of Genetics  
Generally the obesity epidemic is credited largely to environmental influences; 
however, people subjected to comparable environments throughout their life can still 
have varied degrees of predisposition to obesity, and this is attributable to individuals 
having differential genetic makeup(15). It is difficult to prove the precise underlying 
genetic cause of obesity, largely as a result of the complex mechanisms participating in 
the biological management of adiposity. Therefore, further research is required to 
establish the clinical significance of different genetic loci found to be associated with 
obesity. Following is a review of a number of studies that have attempted to uncover 
the genetic components affecting the incidence of obesity; split into monogenic and 
polygenic based analyses.  
 
1.1.2.1 Monogenic Obesity 
In some cases the genetic component of obesity has been established as simply a result 
of rare single-gene mutations producing large effect, this is collectively defined as 
‘monogenic’ obesity. Mouse studies in the mid-1990s revealed the first single gene 
mutation responsible for increased susceptibility to obesity and this was mapped to the 
human homologue LEP (leptin) gene(16). Leptin functions as a cell signalling hormone 
in the regulation of food intake, body weight and appetite; where absence or resistance 
can lead to uncontrolled eating and weight gain. Since then research analysing single 
gene mutations have revealed numerous genes now known to play a role in Mendelian 
forms of obesity (Table 1.1). These single gene mutations have overtime lent insight 
into the genetic nature of this disease, along with uncovering a number of different 
biological pathways incorporating these genes that are now known to be implicated 
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during incidence of obesity. MC4R (Melanocortin 4 Receptor) is the most common 
single-gene form of obesity that is currently known, explaining about 5% of the severe 
early onset obesity cases(17). MC4R codes for a membrane bound receptor protein that is 
mediated by G proteins and is reported to play an essential role in energy homeostasis 
and somatic growth(18). 
Research surrounding monogenic obesity has become predominantly concerned with its 
relative importance in the development of personalised medicine(15). For example, 
obese patients with LEP mutations can successfully overcome and reverse weight gain 
via leptin replacement(19, 20). However, many studies have challenged the relative 
importance of monogenic forms of obesity in terms of their involvement in the obesity 
epidemic(21, 22), and are perhaps justified as these single-gene variants, although they 
produce a significant effect in the obese phenotype, only account for a minute 
proportion (~5%) of all severe obesity cases(17). Moreover, medical advancements have 
been limited, and leptin deficiency is currently the only monogenic form of obesity 










Table 1.1 Summary of genes associated with monogenic forms of obesity. 










Montague, C.T et al (1997)(24)  
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Oksanen, L. et al. (1997)(26) 
LEPR 1 




onset obesity Clement, K. et al. (1998)(27) 
POMC 2 
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1.1.2.2 Polygenic Obesity 
Polygenic obesity is the term used in research to describe the much more common but 
complex forms of obesity resulting from the interaction of a multitude of different 
single nucleotide polymorphisms (SNPs), along with an interaction with environmental 
components. Studies exploring the genetic foundation of common obesity have been 
largely unsuccessful, that is until technological advancements unearthed novel genomic 
approaches such as genome wide association studies (GWAS). GWAS locate common 
variants associated with common phenotypes such as obesity. Association studies have 
identified many common SNPs associated with obesity and body mass index (Table 
1.2). The FTO (fat mass and obesity associated) gene is known to contribute to the 
regulation of body size and fat accumulation, and even though its exact physiological 
function is not yet known, FTO dominates the genome wide association literature as the 
most common gene nearest obesity associated SNPs(34-36). Similarly, over a range of 
selected GWAS, FTO was the most frequently connected loci to the strongest 
predictive SNP relating to obesity (Table 1.2). Additionally various loci, such as 
MC4R, that have been previously linked with monogenic obesity, also connect to 
common variants (SNPs) associated with complex obesity(22, 37). It is important to note 
that although studies investigating obesity associated genes can be compared, such as in 
Table 2, they often vary in their definitions of obesity. For example one study(38) 
defined obesity by looking at the extremes (>3 SD) of the BMI normal distribution, 
whereas, another study(39) defined obesity by BMI class; BMI ≥ 30 kg/m2 for obesity 
class I, BMI ≥ 35 kg/m2 for obesity class II and BMI ≥ 40 kg/m2 for obesity class III.  
Although GWAS have been able to unearth many single nucleotide polymorphisms 
associated to increased adiposity, almost all of the single nucleotide base changes that 
have been associated with common obesity are not causal. Collectively these common 
variants have poor predictive power, only accounting for ~5% of the total heritability of 
BMI(21, 22, 40, 41). Thus, research is still aiming to explain the remainder of body masses 
missing heritability and answers will require use of further technological advancements, 
such as next generation sequencing, in order to examine rarer variants whilst 
maintaining high predictive power(42).  
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Table 1.2 Summary of the number and strongest associated SNPs with obesity or body mass index from different GWAS.*  
Abbreviations; BMI- Body mass index, Chr- Chromosome, GWAS-Genome wide association studies, SNPs- Single nucleotide polymorphisms  
a The number of associated SNPs with obesity or body mass index from different GWAS with a p-value threshold of p < 10-8 
b Strongest associated SNPs with obesity or body mass index from different GWAS with a p-value threshold of p < 10-8 






Strongest associated SNP 
(nearest gene ; Chr)b 
Odds Ratioc or Beta 
Wen et al. (2014)(43)  Body mass index 86,739 14 rs1558902 (FTO; 16) 0.03-0.08 per BMI unit increase 
Pei et al. (2013)(44)  Body mass index 20,913 2 rs6567160 (MC4R; 18) 0.08-0.09 per kg/m2 increase 
Graff et al. (2013)(45) Body mass index 13,627 6 rs9940128 (FTO; 16) 0.05-0.1  per BMI unit increase 
Monda et al. (2013)(46)  Body mass index 39,144 5 rs7708584 (GALNT10; 5) 0.02-0.07  per BMI unit increase 
Berndt et al. (2013)(39)  Body mass index 16,068 9 rs11075990 (FTO;16) 1.13-1.35c 
Berndt et al. (2013)(39)  Obesity 204,498 58 rs7185735 (FTO; 16)  1.04-1.45c 
Wheeler et al. (2013)(38)  Obesity (early onset, 
extreme) 
6,889 8 rs1421085 (FTO; 16)  1.22-1.67c  
Yang et al. (2012)(47) Body mass index 133,154 1 rs7202116 (FTO; 16)  0.04 per BMI unit increase 
Bradfield et al. (2012)(48) Obesity 13848 2 rs9568856 (OLFM4; 13) 1.14-1.22c 
Okada et al. (2012)(49)  Body mass index 26,620 7 rs12149832 (FTO; 16)  0.04-0.07 per BMI unit increase 
Wen et al. (2012)(50)  Body mass index 27,715 5 rs11671664 (GIPR; 19) 2.55-4.22% increase per BMI unit 
Jiao et al. (2011)(51) Obesity 327 2 rs988712 (BDNF; 11) 1.26-1.36c 
Wang et al. (2011)(52) Obesity 1,060 2 rs17817449 (FTO; 16)  NA 
Speliotes et al. (2010)(53)  Body mass index 123,865 31 rs1558902 (FTO; 16)  0.06-0.39  per kg/m2 increase 
Scherag et al. (2010)(54)  Obesity (early onset 
extreme) 
2,258 2 rs1558902 (FTO; 16)  1.22-1.37c 
Cotsapas et al. (2009)(55)  Obesity (extreme) 3,972 1 rs9941349 (MC4R; 18)  1.48c 
Meyre et al. (2009)(56)  Obesity 2,796 3 rs1421085 (FTO; 16)  1.12-1.39c 
Thorleifsson et al. (2008)(57) Body mass index 73,758 10 rs8050136 (FTO; 16)  3.63-8.04% standard deviation 
Willer et al. (2008)(58) Body mass index 32,387 6 rs9939609 (FTO; 16)  0.07-0.33  per kg/m2 increase 
Loos et al. (2008)(37)  Body mass index 16,876 1 rs17782313 (MC4R; 18) 0.05  per unit increase in log(BMI) 
Frayling et al. (2007)(36)  Body mass index 10,657 1 rs9939609 (FTO; 16)  0.36  per kg/m2 increase 
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1.1.3 Obesity and Cancer Burden  
It is well-known that excess weight gain is linked to an increased risk of many health 
related diseases, particularly heart disease, type 2 diabetes, obstructive sleep apnea, 
osteoarthritis and certain types of cancer(2). Evidence suggests that a large proportion of 
all cancer related deaths in both sexes can be credited to patients carrying excess fat 
mass(59). There is evidence for heterogenic qualities of obesity such as the existence and 
difference between white and brown adipose tissue(14), heritage of adipocyte cells(60, 61), 
and topographical location(62). This heterogeneity has the potential to influence clinical 
outcome, particularly for obese cancer patients(14). Thus, it is important to measure and 
examine obesity as a multifactorial disease as well as analysing the specific 
characteristics of adiposity, when carrying out obesity related research.  
 
BMI is currently the best studied variable for the obesity and cancer relationship, most 
likely because BMI is a universal and well-established indicator of fat mass(59). 
Numerous studies have confirmed that greater BMI is positively correlated with an 
increase in cancer risk and cancer mortality, most notably in cancers of the kidney, 
endometrium, colorectal, pancreas, post-menopausal breast and oesophageal 
adenocarcinoma(63-67). Despite this well-studied and unequivocal BMI-cancer 
relationship, the multifactorial and heterogenic nature of both obesity and cancer means 
that these associations can only be assumed as correlative; the precise mechanisms 
acting during accumulation of excess fat mass causing an increased risk of cancer are 
less well understood(67, 68).  
 
There are four distinct mechanisms that have emerged and currently dominate the 
literature in attempting to explain the pathophysiological epidemiology of obesity-
related cancers. The four mechanisms are generally involved with both tumour 
initiation and tumour progression and include insulin resistance and hyperinsulinemia; 
adipokines expression such as leptin and adiponectin affecting cell growth, migration 
and invasion; obesity related inflammatory markers; and oestrogen producing 
proliferative effects(69-72). Obesity is known to be associated with extended periods of 
increased circulating levels of insulin in the blood (reflecting insulin resistance), a 
condition known as hyperinsulinemia. Hyperinsulinemia, through the blocking of 
IGFBP (insulin-like growth factor-binding protein) production, triggers an increased 
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level of bio-available IGF-I (insulin-like growth factor 1), a potent mitogen and cell 
survival agent, thus acting to enhance and promote tumour initiation and tumour 
growth(73). Interestingly, conditions that can promote insulin resistance include 
inflammation and cytokine secretion, which are themselves mechanisms that can alter 
the tumour microenvironment to promote tumour cell proliferation and angiogenesis(74). 
Increased levels of obesity associated adipose tissue stimulates elevated levels of FFA, 
(free fatty acids) increasing the secretion of bioavailable adipokines (leptin), 
inflammatory cytokines and additional factors such as VEGF (vascular endothelial 
growth factor). Increased leptin levels are commonly observed in the serum of obese 
individuals, and this encourages further inflammatory responses in the adipose tissue, 
forming a proliferative positive feed-back loop(75). Furthermore, leptin is known to 
contribute to the regulation of aromatase and oestrogen by adipose tissues(76), in which 
enhanced oestrogen signalling is linked to an increased cancer risk particularly in 
breast, endometrial and ovarian cancers(77). However, the overall diversity in cancer 
development and progression means it is unlikely that one system is individually acting 
alone in obesity-related cancers(69), but it is important to understand these systems 




1.2 Obesity and Breast Cancer  
1.2.1 Susceptibility and Mortality Rates 
It is well known that obesity can influence susceptibility and survival outcome in 
numerous human cancer types, including breast cancer. In 2011 breast cancer was rated 
the most frequent and prominent source of cancer death in women worldwide(78, 79). 
Research has recognised that carrying excess fat mass increases susceptibility to breast 
cancer primarily in post-menopausal women(4, 80, 81). Epidemiological evidence suggests 
that excess body mass can increase breast cancer risk in post-menopausal women by 
approximately 40%(63). Importantly, excess BMI increases post-menopausal breast 
cancer risk in a non-linear fashion(82).  
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Generally increasing BMI is reported to act as a protective element for breast cancer 
risk in women pre-menopause(83, 84). Although opposing evidence has been presented(4), 
a recent meta-analysis confirmed a clear inverse association between obesity and pre-
menopausal breast cancer risk(85). This study suggests that this link is heavily dependent 
on ethnic variation but suggests that body fat distribution may also play a role. The 
mechanisms responsible for the inversed relationship in pre-menopausal women are 
unclear. Metabolic and hormonal changes that are associated with abdominal adiposity 
have been linked with the risk of pre-menopausal breast cancer and are speculated to be 
causing this reversed relationship(86).  
Obesity can also influence survival outcome in diagnosed breast cancer patients. A 
meta-analysis incorporating epidemiologic evidence from 43 publications assessed the 
relationship between breast cancer outcome and obesity at diagnosis, and determined 
that obese patients had a 66% reduced survival rate compared to non-obese 
counterparts(3). Literature provides a somewhat diverse report on overall survival of 
obese patients compared to breast cancer specific survival rates of obese patients, where 
some evidence suggests that co-morbidity due to obesity in breast cancer patients 
causes more unfavourable overall survival rates(87, 88). However, the above meta-
analysis reported the consequence of obesity to be alike in both overall survival and 
breast cancer specific survival(3).  
Four common hypotheses that may explain why obesity leads to reduced survival for 
breast cancer patients have been proposed. These include obese patients presenting with 
more advanced stages at time of diagnosis(89), having a higher risk of secondary breast 
cancer diagnosis(90), having naturally more aggressive tumours, and more likely getting 
lower doses of chemotherapy compared to non-obese equivalents. Research provides 
extensive evidence for the latter two hypotheses(91-94).  
 
1.2.2 Prognosis and Pathogenesis 
Obesity is associated with hormonal alterations that may be acting to promote breast 
tumourigenesis. There is strong evidence that increased concentrations of endogenous 
oestrogen can intensify the chances of developing post-menopausal breast cancer(95, 96). 
Post-menopause, high levels of aromatase provided by adipose cells, converts 
androgens to oestrogens, therefore increasing the amount of serum oestrogen in obese 
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post-menopausal women, particularly in local breast tissue, compared to normal or 
underweight post-menopausal women(97, 98).  
Research suggests the influence of obesity and weight gain on breast cancer 
susceptibility, and prognosis may fluctuate depending not only on menopausal status, 
mentioned earlier, but also oestrogen and progesterone receptor (ER and PR) 
expression(99-101). Typically ER+PR+ breast cancer tumours are associated with an 
obesity mediated increased likelihood of recurrence and poorer prognosis in post-
menopausal women(102, 103). Conversely, obesity is reported to be associated with an 
absence of hormone dependence and reduced breast cancer risk in pre-menopausal 
women; however, excess fat mass in younger women often results in worse prognosis 
at the time of diagnosis(104, 105).  
 
Obesity is significantly correlated with many traditional prognostic characteristics of 
breast carcinomas. Research confirms the predictive ability of increased BMI for 
presentation of larger tumour sizes, increased involvement of lymph nodes and greater 
chance of metastasis in post-menopausal oestrogen dependent breast tumours(102, 106).  
 
Obesity exerts primary and secondary level effects on breast tumour pathogenesis. 
Weight gain in post-menopausal women parallels an increase in adipose tissue, in 
which adipose tissue is known to yield primary level effects in obesity-mediated breast 
tumourigenesis via secretion of inflammatory cytokines(102) and adipokines (leptin and 
adiponectin)(107, 108), which are associated with increased incidence of breast cancer 
pathogenesis. Furthermore, an increase in weight gain in post-menopausal women is 
indirectly associated with insulin resistance, demonstrated to exert secondary level 
consequences in breast tumourigenesis such as hyperinsulinemia and elevated 
bioavailability of oestrogen(109, 110). Despite the wealth of literature dedicated to this 
area, the precise way in which obesity influences breast tumourigenesis still remains 
relatively unclear. Identification of possible mechanisms that are causing such a direct 
link have become centred on a dominant group of processes, including oestrogen 
signalling, hyperinsulinemia, adipokine expression (adiponectin, leptin) and 
inflammation(72, 110, 111). General conclusions propose the relationship to be almost 
certainly occurring as a result of a complex interaction between these different 
mechanisms(109, 112).  
12 
1.2.3 Obese Breast Tumour Transcriptomic Signature  
Genetic profiling is an informative tool enabling the genetic signatures of a number 
and/or different populations of cells to be identified and compared to each other. 
Analysis of tumour genomic DNA has classified a large cohort of breast tumours into 
four main breast tumour subtypes including, luminal A; luminal B; basal-like; and 
HER2 enriched(113, 114). Currently, the expression of clinical biomarkers (ER, PR and 
HER2 expression) within a patients breast tumour, are utilised by pathologists to 
categorise which of these four established intrinsic subtypes of breast cancer the tumour 
represents. Most luminal A and B tumours are ER+ and/or PR+, HER2-enriched 
tumours are largely HER2+, and basal-like (triple negative) cancers are generally 
negative for all three clinical biomarkers(113, 114). Based on a tumours ER, PR and HER2 
status, breast cancer patients are offered clinical treatments intended to be 
characteristically effective for their individual tumour(114). However, a number of ER+, 
PR+ and HER2+ tumours are still resistant to hormone blocking and anti-HER2+ 
therapies, which are current treatment strategies for targeting the growth of hormone 
dependent tumours(115). The causal mechanisms responsible for this resistance are still 
unclear. Equally so, for tumours with non-dependence on all hormone receptors, giving 
it a basal-like (triple negative) phenotype, means, that not only is the tumour more 
aggressive, it cannot be treated effectively with either of the well-established endocrine 
and anti-HER2 clinical therapies. Consequently, triple negative tumour treatment relies 
predominantly on specifically designed chemotherapy regimens. Previous large scale 
studies have sought to identify novel co-expressing genes associated with ER, PR and 
HER2 breast tumour biomarkers. They suggest that revealing such genes may 
ultimately aid an explanation for the appearance of treatment resistance and/or elucidate 
novel therapeutic targets/treatments, which is particularly important in the case of 
aggressive basal-like tumours(116, 117).  
Although, transcriptomic profiling of breast tumours has recognised these genomic 
patterns connected with clinically important pathological features (113, 114), little research 
has been carried out surrounding the genetic profiles of breast tumour genes in patients 
with differing BMI status, in fact only two studies have developed transcriptomic 
profiles for breast tumours from obese patients(118, 119).  
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The first, Creighton et al., compared breast tumour signatures (n= 103) from normal 
and overweight patients collectively to obese tumour transcript patterns, from which 
they derived 662 genes (p < 0.01) that were being differentially expressed in obese 
versus non-obese tumours(118). Of those genes differentially expressed in obese 
tumours, a high proportion (602 genes) were downregulated in obese tumours and 
linked with nucleus and transcription regulation systems. Similarly, Fuentes-Mattei et 
al. generated comparable transcriptomic data for 137 breast tumours, in which they 
identified 112 significantly differentially expressed genes, associated with 59 biological 
alterations, in tumours from obese oestrogen positive breast cancer patients(119). 
Fuentes-Mattei et al. verified genes involved in the mechanistic pathways associated 
with adipokines as well as oestrogen, insulin and IGF-1 signalling in obesity-enhanced 
oestrogen dependent breast cancer development(119).  
Interestingly, unpublished analysis of data derived from these studies highlights both 
GRIA2 (glutamate receptor, ionotropic, AMPA 2) and DUSP4 (dual specificity 
phosphatase 4) as potentially influential genomic locations in the obesity-breast cancer 
relationship, as both are significantly downregulated in obese patient tumours. GRIA2 
codes for one of four (GRIA1-4) glutamate receptor subunits that join to form a ligand-
activated cation channel in the mammalian brain. The DUSP4 gene product is 
expressed in a variety of different tissues where it is localised to the nucleus and 
functions by inactivating ERK1, ERK2 and JNK via phosphorylation.  
Further analysis comparing transcriptomic signatures generated in these two studies 
will hopefully confirm an overlap between the genetic profiles, and inquiry into this 
overlap may introduce molecular links between obesity and breast cancer and therefore 
informative development of potential prevention and/or treatment targets. 
 
 
1.3 Obesity and AMY1 Copy Number Variation 
1.3.1 Copy Number Variation  
Differences in the DNA sequence of our genome contribute to our overall uniqueness, 
where no two people in the world are genetically identical, not even monozygotic 
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twins(120). There are different forms of variation that appear in the human genome, 
ranging between gross structural alterations to single nucleotide polymorphisms 
(SNPs). Overall, SNPs are extremely common in the human genome but only account 
for a small proportion of the diversity currently acknowledged in human disease(121). In 
contrast, structural variation such as copy number variants, inversions, insertions, 
deletions and duplications, that affect more than just a single nucleotide base, explain a 
much greater proportion of human genetic diversity in comparison to single nucleotide 
changes(122, 123).  
Copy number variation (CNV) is a form of genetic variation present in the human 
genome. A copy number variant is a large structural duplication or deletion in which 
the consequence for the cell is an abnormal gene dosage of one or multiple genes. Copy 
number variants can range anywhere between 1000 nucleotide bases to numerous 
megabases in length. Duplication refers to extra copy/copies of a region and deletion 
refers to fewer than the normal number of copies (Figure 1.1). Research surrounding 
genomic variants has identified and catalogued greater than 100,000 copy number 
variants now regarded as a major source of genetic variation. Research indicates that 
CNV accounts for a significant percentage, approximately 12 %, of the variation 
currently recognised in the human genome(124). The genome is susceptible to de novo 
copy number mutations during human development, but CNV can also be inherited(5). 
CNV has potential clinical relevance in a number of diseases(125), due to the ability of 
copy number variants to influence our phenotypic traits. An example of a copy number 
variant in the human genome influencing susceptibility to common obesity is AMY1(8).  
 
1.3.1.1 Obesity and Copy Number Variants 
Copy number variants are becoming increasingly popular in obesity research. Since 
SNPs classified by GWAS have only been able to partially account for the heritability 
of common obesity(15, 21, 22), there has been a shift toward more predictive power, and 
thus the motivation to assess the role of copy number variants in complex disease, 
including common obesity(121). A large proportion of CNV studies interrogating obesity 
have discovered large rare structural variants linked to obesity(126-128). Except for the 
well-studied 539 kb deletion at 16p11.2, replication of CNV analysis across different 
human populations is currently lacking in the literature. Based on this lack of 
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replication reports discussing correlations between obesity and copy number variants in 
the human genome are currently not as globally significant as well researched SNPs 
linked with common obesity(126, 128). Research has also reported common biallelic copy 
number variants to be related to measures of obesity(129, 130), though common copy 
number variants are highly associated through linkage disequilibrium with SNPs. 
Polymorphisms yield small effect and restricted predictive power, thus the ability of 
common copy number variants in the genome will probably share a similar fate when it 
comes to contributing to the missing obesity heritability(131). Not surprisingly, some 
copy number variants that have been identified to associate with the obesity phenotype 
are at loci also containing common polymorphisms that have been previously linked 
with BMI(57, 127). Overall there is emphasis on the need for future research on complex 
multi-allelic copy number variants which are not as detectable in SNP-based GWAS 
and therefore may play an important role in understanding more about heritability of 
BMI and obesity(22, 132).  
 
1.3.2 AMY1 
1.3.2.1 Properties of Salivary Amylase  
Numerous amylase genes cluster in the human genome on chromosome 1p21, AMY1A, 
AMY1B and AMY1C expressing in saliva and AMY2A and AMY2B in the pancreas. A 
large proportion of saliva proteins are produced by the salivary glands, in which 
salivary amylase is the most abundant of salivary proteins(133). Salivary α-amylase is a 
monomeric protein secreted into saliva that begins the digestion of ingested starch 
molecules in the mouth and oral tract, by catalysing the hydrolysis of 1,4-alpha-
glucoside bonds located throughout oligosaccharide and polysaccharide molecules(134). 
Saliva amylase is the product of AMY1, well-known for its extensive copy number 
variation (CNV) in the human genome, ranging anywhere between 2 and 15 diploid 
copies per individual(6, 7).  
The relative importance of salivary amylase in the digestion of large starchy molecules 
may have initially been underestimated, particularly when compared to pancreatic 
amylase enzymes. Studies have shown that salivary amylase not only has the ability to 
very rapidly modify the molecular structure of complex carbohydrates in the mouth and 
oral tract (134), but that salivary amylase exists and functions throughout the stomach 
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(135). Moreover, once hydrolysis has begun, the somewhat metabolised starch acts to 
protect salivary amylase from stomach acid(136). When collated these findings imply a 
significant contribution of salivary amylase to total amylase concentrations throughout 
the digestive system.  
 
1.3.2.2 Evolution of AMY1 CNV 
Variation in AMY1 copy number at chromosome 1p21 is a stable and heritable genomic 
acquisition that arose during human evolution. Over time the human diet has become 
increasingly dependent on carbohydrate and starchy based foods as our agricultural 
industries have developed. Breakdown of these nutrients begins at the very start of the 
human digestion process where salivary amylase cleaves apart any large starchy 
molecules in preparation for further catalysis in the stomach(134). Studies on salivary 
amylase have established and verified the functional, positive correlation between 
AMY1 copy number and quantity of amylase protein found in saliva, thus influencing 
an increased rate of amylase enhanced starch breakdown(7, 137). Moreover, research has 
confirmed that people coming from populations historically exposed to high starch diets 
have evolved, on average, more copies of AMY1 compared to populations accustomed 
to reduced levels of starch intake(7). Nutritional pressure exerted by high starch diets 
over time represents a strong positive selection on AMY1 and subsequent salivary 
amylase production, causing the independent duplication of copy number in different 
populations around the world, thereby facilitating an increase in amylase induced starch 
metabolism(7, 138). These findings indicate the critical role of salivary amylase in the 
digestion of large starchy molecules regularly consumed in the human diet.  
 
1.3.2.3 AMY1 and Obesity 
AMY1 CNV is linked with a predisposition to obesity. A recent study by Falchi et al.(8) 
analysed gene expression data from adipose cells of 149 Swedish families with siblings 
that differed significantly in BMI using quantitative polymerase chain reaction (qPCR), 
and examined physiologically important copy number variants based on their ability to 
impact dosage of gene products; the study identified a single CNV region incorporating 
the amylase gene(8). After replicating their findings in a total of just over 6,000 subjects, 
the researchers were able to conclude a dosage dependent affect associated with AMY1 
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CNV and a predisposition to obesity (Figure 1.2)(8). The study argued that variation in 
AMY1 copy number may explain somewhere between 2.5% and 20% of the total 
heritability associated with obesity(8), more than previously acknowledged by 
Mendelian variants and hundreds of common polymorphisms.  
Falchi et al. findings(8) prompted Maria et al. in Mexico, where childhood obesity rates 
are of great concern, to assess the role of AMY1 dosage in these children. Six hundred 
children from all around Mexico were sampled, with a ratio of 1:1, obese and normal 
weight according to BMI. AMY1 copy number was assessed using digital polymerase 
chain reaction (digital PCR), and analogous to Falchi et al., researchers concluded there 
was a notable dosage effect of AMY1; subjects with greater than 10 copies of AMY1 
were all normal weight according to BMI scoring(139).  Similarly, researchers in Finland 
have recently demonstrated that AMY1 CNVs, specifically lower copy number, are 
associated with early-onset childhood obesity; however this association was only 
evident in young females(140).  
 
 
Figure 1.2 Low dosage of AMY1 has been credited as a significant risk factor toward accumulation of 
excess fat mass in people of European origin. 
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Despite the growing support in the literature for the inverse correlation between AMY1 
copy number and obesity, there is an undeniable discordance between what Falchi et 
al.(8) initially reported and what population based GWAS have revealed about the 
genetic contributions of common obesity. The amylase locus is structurally complex, 
making CNV not only especially difficult to calculate but challenging to derive 
connections with obesity susceptibility(141), questioning perhaps the choice of technique 
used in AMY1 copy number derivation. A recently published study looking at AMY1 
copy number in a large multi-ethnic cohort, reported no association between AMY1 
copy number and BMI, and suggested that the disagreement is attributable to their use 
of higher resolution techniques, being digital PCR, for determining AMY1 copy 
number(142). Table 1.3 represents all of the current reports surrounding obesity and 
AMY1 CNV, and the cohorts and techniques used to determine their findings.  
 
 
AMY1 Copy Number Variation and Obesity 
 Inverse Correlation No Correlation 
Quantitative 
PCR 
Falchi et al. 2014 (n=6,200) 
 
Digital PCR Mejia-Benitez et al. 2014; (n=597) 
Viljakainen et al. 2015 (n=132) 




There is clearly a need for research examining complex multi-allelic copy number 
variants to understand more about the heritability of obesity.  AMY1 represents the type 
of CNV that can fill this gap. The recently reported association between AMY1 CNV 
Table 1.3 Summary of the literature, to date, that has reported on AMY1 copy number variation 
and its association with obesity, using either quantitative PCR or digital PCR to determine the 
status of the correlation. The study’s authors, year of publication and the number of patient 
samples investigated are represented within each of the categories.  
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and a predisposition to obesity potentially explains some of the fairly large amount of 
missing heritability of human obesity.  
Falchi et al. and Maria et al. are the first two studies of their kind, establishing a genetic 
link between digestion of starchy foods and predisposition to obesity(8, 139). 
Furthermore, Falchi et al. reported a greater association between BMI and AMY1 copy 
number, than between BMI and FTO SNPs, contradicting the currently dominant 
literature valuing FTO as the strongest associated loci with susceptibility to obesity in 
humans (Table 1.2). Interestingly, further investigation of the extensive genome wide 
meta-analysis carried out by Speliotes et al., examining SNPs associated with measures 
of obesity, revealed a significant interruption of SNP reportage across the region 
incorporating AMY1(53).  Therefore, it is possible that increased structural variation such 
as large duplications or deletions, occurring in the amylase cluster, may obstruct the 
ability of GWAS locating SNPs in such genomic regions.  
All of the above is evidence that CNV provides a relatively novel and largely 
unexplored component of the human genome. Further investigation of copy number 
variants, particularly those including AMY1, may answer some of the literature’s 
pending questions, such as the missing obesity heritability, and the adverse health risks 
associated with weight gain, for example, obesity linked incidence and mortality of 
breast cancer.  
 
 
1.4 Research Hypotheses  
The prevalence of obesity is increasing at an alarming rate worldwide(1). Obesity is 
recognised for its involvement in amplifying risk of adverse health effects, with 
particular concern focused on the increase in obesity associated breast cancer incidence 
and mortality worldwide(3, 4). Regardless of past and current research supporting the 
positive correlation between obesity and breast cancer risk, the molecular basis and 
precise mechanistic properties of the association between obesity and increased breast 
cancer risk and development still remain unclear.  
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In the same way that past explorations have used genomic techniques to identify breast 
tumour subtypes, which can be treated with certain therapies for the most effective 
clinical outcome(114), it could be postulated that similar research may be able to 
determine genetic signatures and subsequent clinical therapies unique to obese breast 
tumours. It is conceivable that an obesity associated tumour initiation mechanism is not 
evident, or is transpiring at a less frequent rate in tumours arising in healthy weight 
women. Tumour gene expression analysis, of obese compared to healthy breast 
tumours, could reveal genes responsible for this suspected obesity associated breast 
tumour initiation system. Previous genetic profile studies have identified genes that 
may be associated with breast tumour phenotype in obese women(118, 119). Although 
these intriguing findings suggest a potentially important relationship between genetic 
risk and molecular phenotype of breast tumours, this still requires further research with 
a well characterised cohort of breast cancer cases.  
Additionally, recent research has demonstrated a clear inverse association between 
germline DNA copy number of the AMY1 gene and the risk of obesity(8). Conflict in the 
literature proposes that this inverse correlation is variable across different study 
cohorts. Therefore, although the association between AMY1 copy number and obesity 
risk may be controversial(8, 142), the established genetic association between AMY1 copy 
number variation and increased weight gain has not yet been examined in normal and 
obese breast cancer patients, despite the already well supported link between obesity 
and breast cancer.  
Hypothesis: Based on the above it has been hypothesised for the current study that 
obese breast cancer patients are associated with (1) low germline AMY1 copy number 
and (2) differential expression of other candidate genes in their breast tumours. In order 
to test the first section of this hypothesis, research was focused on determining whether 
lower AMY1 copy number is inversely correlated with increased body mass index 
(BMI), in breast cancer patients. The second section of this hypothesis explored the 
molecular phenotype of breast tumours arising in women with differing BMI status, by 
investigating two research objectives. Initially, by selecting candidate gene markers for 
obesity associated breast cancer based on what is already known about the 
transcriptome of breast tumours arising in women with differing BMI status. Lastly, by 
analysing the gene expression profiles of these candidate gene markers in obese 
compared to healthy weight breast tumours.  
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For comparative purposes this project involved the recruitment of two cohorts of breast 
cancer patient samples; those considered healthy weight (BMI < 25) and those 
considered obese (BMI > 30) according to BMI scoring. Comparison between obese 
and healthy weight breast cancer patients was carried out on 55 blood and 40 





Chapter 2  
2 Materials and Methods  
2.1 Patient Samples and Tumour Specimens 
A total of 16 pre-menopausal and 39 post-menopausal patients with histologically 
diagnosed breast cancer tumours available from The Cancer Society Tissue Bank were 
used in this study(143). Sample selection was biased towards postmenopausal women 
(>55 years) and the patients recorded BMI at the time of sample collection. Twenty-
seven patients with a BMI greater than 30 and twenty-eight patients with a BMI less 
than 25 were chosen. Available clinicopathological data was also obtained for all 55 
samples, including age at onset; BMI; oestrogen and progesterone receptor status; 
ERBB2 (HER2) expression; histological type and grade; and ethnicity (Table 2.1). 
Samples were approximately evenly split within each of these clinicopathological 
features among the obese and healthy cohorts.  
The Cancer Society Tissue Bank only collects samples from which patients have given 
consent for banking and pertinent future research use. The University of Otago Ethics 
Committee approved the use of the banked samples and their available 
clinicopathological data (approval number H14/131).  
The samples collected from The Cancer Society Tissue Bank were in the form of 55 
patient FTA® blood cards (Whatman, Thermo Fisher Scientific, Albany, Auckland, 
New Zealand) and 40 overlapping fresh frozen tissue samples. The blood samples are 
taken from the consenting patient during pre-surgical blood collection and delivered 
along with notice of the patients’ timetabled day of surgery. The tissue bank curator 
snap freezes all tissue samples in liquid nitrogen (-196 °C) as quickly as possible after 







Table 2.1 Summary of the clinicopathological data for breast cancer patient samples used in this 
study. 
ER- Oestrogen Receptor; HER2- Human Epidermal Growth Factor Receptor 2; IDC- Invasive 
Ductal Carcinoma; PR- Progesterone Receptor 
  
  Patient Blood Samples (n)  Patient Breast Tumours (n) 
  BMI<25 BMI>30 Total  BMI<25 BMI>30 Total 
Obesity 27 28 55  18 22 40 
Menopause        
 Pre- 8 8 16  0 2 2 
 Post- 19 20 39  19 19 38 
Grade        
 1 2 1 3  2 1 3 
 2 9 7 16  6 4 10 
 3 16 20 36  11 16 27 
ER        
 Positive  20 20 40  13 15 28 
 Negative  6 7 13  6 5 11 
 Unknown 1 1 2  0 1 1 
PR        
 Positive  19 17 36  12 13 25 
 Negative  8 8 16  7 6 13 
 Unknown  0 3 3  0 2 2 
HER2        
 Positive  4 6 10  3 6 9 
 Negative  18 18 36  10 12 22 
 Unknown  6 3 9  6 3 9 
Histological Type        
 IDC 15 17 32  10 14 24 
 Other 12 11 23  9 7 16 
Ethnicity        
 NZ European  26 24 50  19 18 37 
 Maori  0 3 3  0 2 2 
 Other 1 1 2  0 1 1 
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2.2  Nucleic Acid Extraction  
2.2.1 DNA 
2.2.1.1 FTA® Extraction  
Blood was extracted from FTA® cards using QIAamp DNA mini kit (Qiagen, Venlo, 
Linburg, Netherlands). FTA®cards trap lysed blood cells and provide a mechanism for 
germline DNA preservation. Punches (0.3 mm) were taken from blood stained FTA® 
cards for all 55 breast cancer patient samples. ATL buffer (tissue lysis buffer used for 
the purification of nucleic acids) and proteinase K were added to the FTA® punches in a 
microcentrifuge tube and incubated at 56 °C with shaking at 1,400 rpm for 1.5 hours. 
After incubation the extracted DNA was purified using the spin column/collection tubes 
and wash buffers from the QIAamp DNA mini kit (Qiagen, Venlo, Linburg, 
Netherlands). Optimisation required using 4 x 3 mm FTA® punches, 420 μL of ATL 
buffer and 60 μL of proteinase K to get sufficient DNA in the final 50 µL volume 
sample. 
 
2.2.1.2 Quantification of extracted DNA  
DNA purity and yield, was quantified by measuring the A260/A280 absorbance ratio 
on the ND-8000 spectrophotometer (NanoDrop Technologies, Rockland, DE). Sample 
DNA at concentrations greater than 5 ng/µL were required, to ensure that after a 1:2 
dilution there was still sufficient DNA from each patient sample for quantitative PCR 
(qPCR).  
 
2.2.2 RNA Extraction and cDNA synthesis  
Breast cancer tumour samples stored frozen at -80 ºC were collected from The Cancer 
Society Tissue Bank for the 40 breast cancer patients described above, matching with 
the blood samples used for germline DNA extraction. Frozen tumour samples were 
treated with liquid nitrogen and homogenised by crushing into a powder using a mortar 
and pestle held on dry ice.  
 
The mRNA was then extracted from the frozen breast tumour powder using TRIzol 
Reagent® (Invitrogen Corporation, Carlsbad, California, USA) and chloroform (5:1) 
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and centrifuging for 15 minutes at 12,000rpm in 4 °C. The clear aqueous phase 
containing the RNA was collected, and the remaining DNA and protein phases were 
frozen at -80 °C. The aqueous RNA phase was purified using the RNA clean-up and 
concentration kit (Norgen Biotek Corporation, Thorold, Ontario, Canada; Cat# 23600). 
RNA yield was quantified using a Qubit™ RNA assay (Invitrogen Corporation, 
Carlsbad, California, USA).  
 
 
2.3 Protein Extraction and Purification  
The remaining DNA and protein phases frozen after RNA extraction for all 40 breast 
cancer tumours were treated with 300 µL of 100% ethanol and centrifuged at 2000 rcf 
for 5 minutes at 4 °C to pellet the DNA. The phenol-ethanol supernatant containing the 
tumour protein was collected and the remaining DNA pellet was frozen at -20 °C. The 
protein in the phenol-ethanol supernatant was collected and pelleted by centrifugation 
at 12,000 rcf for 10 minutes at 4 °C. The protein pellet was washed using 2000 µL of 
0.3 M guanidine hydrochloride in 95% ethanol multiple times before being resuspended 
in 200 µL of 1% sodium dodecyl sulphate (SDS) by sonication. Insoluble material was 
removed and remaining soluble protein supernatant was used for Western blotting. 




2.4 Bioinformatics  
The bioinformatic analysis focused on two different studies with publically available 
datasets. Searching “breast cancer gene expression signature obesity” in PubMed 
specifies 10 papers, of which two provide usable breast tumour gene expression data 
for the purpose of this study; one by Creighton et al.(118)and the other by Fuentes-Mattei 
et al.(119). 
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NextBio (https://www.nextbio.com) was used to gather breast cancer data generated by 
Creighton et al.(118) by searching for studies exploring ‘obesity’ and ‘breast cancer’. A 
comparison of gene expression between ‘obese (BMI > 30)’ vs ‘healthy (BMI < 25)’ 
breast cancer patients according to BMI scoring was conducted. Creighton et al.(118) did 
not exclude the overweight group from their analysis; hence Nextbio was used to 
generate the ‘obese’ vs ‘healthy’ association. Only the top 100 of the most statistically 
differentially expressed genes from Creighton et al.(118) were selected for the current 
analysis.  
The supplementary material from the Fuentes-Mattei et al.(119) study reported changes 
in gene expression after comparing ER+ breast tumours from obese (BMI > 30) and 
non-obese (BMI < 30) women. BMI data was not reported by Fuentes Mattei et al. 
(2014) and therefore non-obese patients could not be split between healthy and 
overweight. Thus, the non-obese category used by Fuentes-Mattei et al.(119) was treated 
as comparable to ‘healthy + overweight’ used by Creighton et al.(118).  
Lastly, gene duplicates were removed for any genes that appeared more than once in a 
dataset due to multiple probe ID callings. 
 
 
2.5 Quantitative Polymerase Chain Reaction (qPCR)  
2.5.1 AMY1 Copy Number Assay 
2.5.1.1 Primer/Probes  
Three pre-designed different primer/probes were used for relative copy number analysis 
including, RNase P (ribonuclease P) and two different AMY1 target primer/probes with 
varying amplicon length (Invitrogen Corporation, Carlsbad, California , USA) (Table. 
2.2). These primer/probe assays were chosen because they were used successfully in a 
previous nature genetics paper that explored germline AMY1 copy number variation 
(CNV) in the human genome(8). RNase P was used as the reference assay which maps 
within the single exon RPPH1 gene, the Ribonuclease P RNA component H1. Both 
AMY1 primer/probes were used as a method of validation, both mapping the same exon 






Table 2.2 Copy number assay primer/probes. 
Target Assay ID/Catalog Number Amplicon Length 
AMY1 Hs 07226361_cn 81 bp 
AMY1 Hs 07226362_cn 101 bp 




2.5.1.2 Quantitative PCR 
Quantitative PCR was carried out using the Roche LightCycler® 480 II (Roche Applied 
Science, Indianapolis, IN, USA). The quantitative PCR protocol that was followed is 
the KAPA Probe Fast qPCR Kit Master Mix (2x) Universal for the 384 well plate. 
Assay optimisation indicated, due to AMY1 having potentially a 7 fold increase in 
primer targets compared to RNase P, that primer limiting allowed RNase P to reach 
plateau, confirming the use of 10x AMY1 primer/probe and 20x RNase P reference 
primer/probe reaction concentrations. Final reaction volumes included 1.5 µL of 
extracted target DNA, 1.5 µL of DEPC-treated water and 7 µL of the reaction Master 
Mix which included 5 µL of the 2x KAPA Probe Master Mix, 0.5 µL of 10x AMY1 
primer/probe (FAM™ dye–labelled)(Life Technologies, Carlsbad, CA, USA), 0.5 µL 
of 20x Ribonuclease P (RNase P) reference primer/probe (VIC® dye–labelled)(Life 
Technologies) and 1 μL of DEPC-treated water. Each PCR run had a ‘no template’ 
control (7 μL of Master Mix and 3 μL DEPC-treated water), HapMap samples 
NA18956 and NA18972 at 1 ng/μL with known copy number of 6 and 14, respectively, 
and a DNA sample of known AMY1 copy number acting as an internal calibrator across 
the different reactions. Each sample was run in triplicate for both AMY1 Hs07226361 
and Hs07226362 assay ID primer/probes.  
The PCR included an activation step at 95 °C for 10 minutes, followed by 40 cycles of 
denaturation (95 °C, 20 sec) and annealing (60 °C, 1 min) and finally cooling for 2 
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minutes at 37 °C. Fluorescence was measured once each cycle at 465-510 nm (FAM™ 
dye–labelled) and 533-580 nm (VIC® dye–labelled), after primer extension.  
Relative expression values were calculated by the LightCycler® Software (Roche). 
Relative quantification was calculated using the comparative Ct model following the 
arithmetic formula 2(-ΔCt)(144). ΔCt is the difference between the mean Ct values of the 
target gene and the assumed two copy number reference gene, RNase P. Mean Ct or the 
threshold cycle for each sample is inversely proportional to the amount of DNA 
present, and was calculated as the fractional cycle number averaged across the three 
replicates at which the fluorescence emitted exceeds the background threshold. The 
threshold for the detection of the sample during PCR was set above the background 
fluorescence and fell within the exponential phase of DNA amplification. Copy number 
of AMY1 for each sample was calculated using two HapMap samples, NA18956 and 
NA18972, with known copy number of 6 and 14, respectively, to which each sample 
was normalised.  
 
2.5.2 qPCR Analysis of Gene Expression Levels 
2.5.2.1 cDNA Synthesis 
Reverse transcription of the extracted mRNA from each breast tumour to get first-
strand cDNA was carried out immediately after extraction and purification, using 
Superscript® III First Strand Synthesis System for RT-PCR (First Strand Kit; 
Invitrogen, Carlsbad, California, USA). Each 20 μL reaction included 10 μL of 2x RT 
Reaction Mix (including, oligo[dt]20 [2.5 μM], random hexamers [2.5 ng/μL], 10 mM 
MgCl2 and dNTPs), 2 μL of RT Enzyme Mix (including, Superscript
® III RT and 
RNaseOUTTM) and 8 μL of extracted mRNA. Reactions were mixed together, 
centrifuged and placed under reverse transcription conditions, including incubation for 
10 minutes at 25 °C, then 30 minutes at 50 °C and finally termination at 85 °C for 5 
minutes. 1 μL of E.coli RNase H was added to each reaction, followed by 20 minutes 
incubation at 37 °C. Each reverse transcription run included a ‘no template’ control. 
The samples were frozen at -20 °C until used for quantitative PCR. 
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2.5.2.2 Primer design 
Primers were designed for 5 genes including, GRIA2, DUSP4, NR2F1, ADH1B and 
EEF1A1 (Table 2.3). Primers were designed using Primer3 version 0.4.0. All gene 
sequences were taken from the U.S. National Centre for Biotechnology Information 
(NCBI). The primers were selected to span adjacent exons acknowledged as reliable 
matches for the gene of interest. The National Centre for Biotechnology Information 
(NCBI) Primer-BLAST tool was used to validate the specificity of the primer sets. 
Primers were synthesised by Integrated DNA Technologies (IDT) and suspended in 
DEPC-treated water to a final concentration of 50 μM and stored at -20 °C.  
 
 
Table 2.3 SYBR® primer sequences. 
 
 
2.5.2.3 Quantitative PCR 
Quantitative PCR was carried out using the Roche LightCycler® 480 II (Roche Applied 
Science, Indianapolis, IN, USA). For the purpose of this study the quantitative PCR 
protocol followed is the Platinum® SYBR® Green qPCR SuperMix-UDG for a 384 well 
plate. Each reaction 0.075 μL of target cDNA (reverse transcribed extracted mRNA), 
2.925 μL of DEPC-treated water and 7 μL of the reaction Master Mix which included 




























3.75μL of SYBR Green Master Mix, 0.375 μL of both forward and reverse primers at 5 
μM for the selected target and 2.5 μL of DEPC-treated water. Each PCR run contained 
both ‘no template’ controls (7 μL of reaction Master Mix and 3 μL DEPC-treated 
water) and reverse transcription negative controls (7 μL in reaction Master Mix and 3 
μL of first-strand cDNA negative control). Each sample was run in triplicate.  
 
The PCR included an activation step at 95 °C for 10 minutes, followed by 40 cycles of 
denaturation (95 °C, 15 sec) and annealing (60 °C, 1 min).  Fluorescence was measured 
once each cycle at 465-510 nm after primer extension. After amplification a melting 
curve was commenced by lowering the temperature to 60 °C for 1 minute before 
continually increasing the temperature (11 °C per second) to 95 °C and measuring the 
fluorescence throughout melting. Finally, the plate was cooled for 30 seconds at 40 °C.  
 
Relative expression values were calculated by the LightCycler® Software (Roche), 
where relative quantification was calculated using the comparative Ct model using the 
arithmetic formula 2(-ΔCt)(144). ΔCt is the difference between the mean Ct values of the 
target genes (GRIA2, DUSP4, NR2F1 and ADH1B) and the reference gene (EEF1A1). 
Mean Ct or the average threshold cycle for each sample is inversely proportional to the 
amount of cDNA present and was calculated as the fractional cycle number averaged 




2.6 Digital Polymerase Chain Reaction 
2.6.1 Sample Selection 
A recent publication has suggested that the sensitivity of quantitative PCR (qPCR) in 
insufficient for copy number calling and that digital PCR is more suitable(142). For 
comparative purposes 3 of the 55 blood samples from the breast cancer patients used 
for AMY1 copy number analysis using qPCR were selected for copy number 
investigation using digital PCR. The 3 samples chosen were all healthy weight patients 
and based on qPCR results, covered a range of AMY1 copy number variants (6-15 
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AMY1 copies). Patient germline DNA was extracted from FTA cards following the 
FTA extraction process described earlier. DNA sample concentrations were determined 









2.6.2 DNA Digest  
The QuantStudio 3D digital PCR system requires each target region (ie. each AMY1 
copy) to be in a discrete well, in the digital PCR chip, for accurate quantification. To 
ensure this a DNA digest was designed to cleave within AMY1 but leaving the amplicon 
site uncut. The restriction enzyme used was HindIII, which cuts at 5’-A|AGCTT-3’. All 
HindIII restriction sites within AMY1 were resolved using genome browser. The 
restriction enzyme was chosen because it was not effected by methylation and it did not 
cleave within either the AMY1 amplicon or the RNase P reference gene (Supplementary 
Figure 6.1).  
 
The controls used for this assay included a ‘no template’ control, a genomic DNA 
sample of known copy number (92.1 ng/µL) and the two HapMap DNA samples 
NA18956 (345 ng/µL) and NA18972 (331 ng/µL) with AMY1 copy number of 6 and 
14, respectively. Digests for controls were carried out in 50 µL reaction volumes 
including 3 µL of HindIII (20 U/mL) restriction enzyme (New England Biolabs, 
Ipswitch, Massachusetts, USA), 30 µL of 10X NEBuffer 2 (New England Biolabs, 
Ipswitch, Massachusetts, USA), 300 ng total DNA and remaining volume of water.  
 
Patient Sample BMI DNA (ng/µL) 
5 19.34 0.40 
8 24.34 0.49 
22 18.02 0.48 
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Due to the low DNA concentrations of the samples, digests were carried out in 30 µL 
reaction volumes. Reaction volumes included, 1.5 µL of HindIII (20 U/mL) restriction 
enzyme (New England Biolabs, Ipswitch, Massachusetts, USA), 5 µL of 10X NEBuffer 
2 (New England Biolabs, Ipswitch, Massachusetts, USA) and 23.5 µL of sample DNA. 
DNA digests were incubated for 16 hours at 37 °C before increasing the temperature to 
80 °C for 20 minutes to denature the enzyme.  
 
2.6.3 Digital PCR 
A digital PCR reaction involves a 20,000 well chip, PCR cycling and chip analysing on 
the QuantstudioTM 3D Digital PCR system (Thermo Fisher Scientific, Rockford, IL, 
USA). Each individual chip used in this experiment investigated AMY1 copy number 
status for a single sample. The samples analysed included 3 patient germline DNA 
samples. Digital PCR chips were loaded as per manufacturer protocols. In brief, a total 
reaction volume of 16 µl containing, 7.25 µl of QuantStudioTM 3D Master Mix 
(Thermo Fisher Scientific, Rockford, IL, USA), 0.725 µL AMY1 primer/probe (FAM™ 
dye–labeled)(Life Technologies, Carlsbad, CA, USA), 0.725 µL of 20x Ribonuclease P 
(RNase P) reference primer/probe (VIC® dye–labelled)(Life Technologies) and 7.3 µl 
of the digested DNA samples, was all loaded onto one chip. Loading was performed 
using the QuantStudio™ 3D Digital PCR Chip Loader, before chips were placed on a 
flat block thermocycler fixed at an 11° angle. The thermocycling reaction consisted of 
an initial activation step at 96 °C for 10 minutes, then 40 cycles of annealing (60 °C, 2 
minutes) and denaturation (98 °C, 30 sec), and ending with cooling for 2 minutes at 60 
°C. Chips were held at 10 °C until fluorescence was analysed. Fluorescence was 
measured once at the end of PCR on the QuantStudio™ 3D Digital PCR Instrument, to 
determine of the 20,000 wells per chip, the number of wells occupied by a target, 
reference, both or neither of these molecules. Fluorescence data was analysed using the 
online QuantStudio 3D AnalysisSuite Cloud Software, which calculates copies/µL of 
the AMY1 and RNase P genes in each sample based on a Poisson distribution. Copy 
number is calculated by calibrating each AMY1 target to its RNase P reference and 
lastly normalising to the HapMap samples NA18956 and NA18972, with known AMY1 
copy number of 6 and 14, respectively.  
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2.7 Western Blotting   
2.7.1 Protein Quantification  
Total protein concentrations for each tumour sample after protein extraction and 
purification were determined using the PierceTM BCA Protein Assay Kit (Thermo 
Fisher Scientific, Rockford, IL, USA) in order to ensure equal protein loading into the 
gel (n=36). A standard curve was constructed using BSA (0-1000 μg/μl) following 
microplate recommendations and reading absorbance at 562 nm on the wallac 1420 
Victor3 plate reader (PerkinElmer Life and Analytical Sciences, Massachusetts, USA) 
(Supplementary Figure 6.2). The standard curve was used to extrapolate from and 
calculate the extracted protein concentration for each tumour sample.  
 
2.7.2 SDS-Page 
Each protein sample was made up to a final volume of 200 μl at 1 μg/μl including, 100 
μl of 2 μg/μl protein in PBS, 50μl of 4X NuPAGE® LDS sample buffer (Novex, Life 
Technologies, Carlsbad, CA, USA), 20 μl of 1M DTT (dithiothreitol) (Sigma-Aldrich, 
St. Louis, MO, USA) and 30 μl of water.  The samples were heated to 70 °C for 10 
minutes before loading into NuPAGE® 4-12% Bis-Tris Gel (Novex, Life 
Technologies). According to the protein loading optimisation Western blots for DUSP4 
required 10 μg of total protein and 40 µg of total protein for GRIA2, loaded into each 
well. On each gel 4 μl of SeeBlue® Plus2 Prestained Standard (Novex, Life 
Technologies) was loaded and gels were run at 125V for 65-70 minutes using 1X 
NuPAGE® MOPS SDS Running Buffer (Novex, Life Technologies).  
 
2.7.3 Transfer 
PVDF membranes were incubated for 10 seconds in methanol for activation. The 
transfer setup (Supplementary Figure 6.3) was used to transfer protein from gel to 
PVDF (polyvinylidene fluoride) transfer membrane (Thermo Fisher Scientific, 
Rockford, IL, USA). Transfer used 1X BlotTM Transfer buffer (Novex, Life 
Technologies) with 10% methanol at 25V for 1 hour. GRIA2 and DUSP4 membranes 
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were blocked with 5% milk in TBS-tween 20 (Sigma-Aldrich, St. Louis, MO, USA) for 
1 hour before antibodies were introduced.  
 
2.7.4 Antibodies  
The primary antibodies for GRIA2 and DUSP4 were analysed in breast tumour samples 
(n=36). The anti-ionotropic glutamate receptor 2 (GRIA2) rabbit monoclonal primary 
antibody (EP966Y) (Abcam, Cambridge, MA, USA) was used at an optimised 
concentration of 1/500 with 5% skimmed milk in TBS-T incubated overnight at 4 °C. 
The anti-DUSP4 C-terminal rabbit polyclonal primary antibody (Abcam, Cambridge, 
MA, USA) was used at manufacturers instructed concentration of 1/500 with 5% 
skimmed milk in TBS-T incubated overnight at 4 °C.  
The DUSP4 blot was stripped with two 25 µL washes of mild stripping buffer (mild 
stripping buffer includes: 1.5 g glycine, 1 mL 10% SDS and 1 mL Tween20; made up 
to 100 µL and adjusted to pH 2.2). The stripped blot was blocked with 5% skimmed 
milk in TBS-T and re-probed for β-actin. The GRIA2 blots were cut to separate the 
GRIA2 and β-actin bands, before probing with primary antibodies. The β-actin primary 
antibody used was mouse monoclonal anti-β-actin antibody (Sigma-Aldrich, St. Louis, 
MO, USA) and was used at 1/10,000 with 5% milk in TBS-T and incubated for 1 hour.  
Blots were washed with TBS-T and secondary antibodies were applied. The polyclonal 
goat anti-rabbit immunoglobulins/HRP secondary antibody (Dako, Glostrup, 
Copenhagen, Denmark) was used for both GRIA2 and DUSP4 blots at 1/5000 in TBS-
T for 1 hour at room temperature. The secondary antibody used for β-actin was the goat 
anti-mouse polyclonal immunoglobulins/HRP antibody (Dako, Glostrup, Copenhagen, 
Denmark) used at 1/10,000 in TBS-T incubated for 1 hour. PVDF membranes were 
imaged by chemiluminescence on the Alliance 4.7 (Uvitec Cambridge, Cambridge, 
UK), after applying Amersham ECL primer Western blotting detection reagents (GE 
Healthcare, Little Chalfont, Buckinghamshire, UK). 
Due to barely detectable GRIA2 expression and dense background disguising the 
bands, the GRIA2 blots were re-wet with methanol for 30 seconds, blocked and re-
probed following the above protocol.  
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2.7.5 Relative expression  
The Western blot bands were quantified using Image J software. The DUSP4 and 
GRIA2 densitometry values were compared to their respective β-actin bands to 
calculate relative expression values. Relative expression values for each sample were 
then normalised across gels using the positive control sample run on each gel.   
 
 
2.8 Statistical Analysis  
Welch T-tests were performed on mean expression data or copy number estimates 
between breast cancer patient groups stratified by clinicopathological features. A P-
value less than 0.05 was considered as statistically significant. 
In order to visualise the change in mean expression data or copy number estimates data 







3 AMY1 Copy Number Analysis   
3.1 Introduction  
There is a strong link between obesity and increased incidence and reduced survival 
rate in diagnosed breast cancer patients, particularly in post-menopausal women(3, 4). 
Despite the vast array of evidence that supports the strong association between obesity 
and breast cancer, the precise underlying mechanisms responsible for such a strong link 
are not that well understood.  
A form of germline alteration known as copy number variation (CNV) has become 
increasingly popular in molecular based obesity research. Copy number variants are 
large structural duplications or deletions which may overlap gene regions, resulting in 
variable gene dosage. These variants have been implicated in many different human 
diseases, including increasing susceptibility towards obesity(121), such as the CNV 
region overlapping the AMY1 gene(7). Recent research has demonstrated a clear inverse 
association between germline DNA copy number of the AMY1 gene and the risk of 
obesity(8). AMY1 codes for the salivary amylase protein, functioning at the beginning of 
the human digestion process, which breaks down large starchy molecules in the diet, as 
preparation for further catalysis in the stomach. A case-control study in Mexican 
children also reported an overall dosage dependent association between AMY1 copy 
number and risk of obesity, and that higher AMY1 dosage is a protective factor against 
obesity(139). A further study in Finland showed an increased risk of early-onset 
childhood obesity associated with lower AMY1 copy number in females, but not in 
males(140). Interestingly, however, a very recent publication investigated germline 
AMY1 copy number in a large multi-ethnic cohort totalling approximately 3,500 
individuals and reported no correlation between AMY1 copy number and risk toward 
increased BMI(142).  
Despite the now controversial but recently well supported link between obesity and 
AMY1 CNV, the proposed genetic association between AMY1 CNV and increased 
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weight gain has not yet been examined in normal and obese breast cancer patients. The 
aim of this study was to identify whether germline AMY1 copy number has a molecular 
link with breast cancer through its association with obesity. 
 
 
3.2 Experimental Design and Research Aims 
In this chapter, DNA was analysed from 55 breast cancer patient blood samples sourced 
from The Cancer Society Tissue Bank, 27 of which were categorised as healthy weight 
(BMI < 25) and 28 as obese (BMI > 30) according to BMI scoring (see Table 2.1 for 
patient clinicopathological data). Quantitative PCR was used to determine germline 
AMY1 copy number for comparison between healthy and obese BMI groups (section 
2.5.1).  
To examine AMY1 copy number calculated using different experimental techniques, 
digital PCR was also utilised to measure AMY1 copy number in three of the 55 blood 




3.3.1 Germline AMY1 Copy Number in Obese Relative to Healthy Breast Cancer 
Patients 
The germline AMY1 copy number in obese compared to healthy breast cancer patients 
shows a definite trend toward lower copy number of AMY1 in obese breast cancer 
patients (Figure 3.1). Two different AMY1 primer probe assays were investigated in this 
chapter, the Hs07226361_cn (AMY1-61) and the Hs07226362_cn (AMY1-62) AMY1 
assays. AMY1-61 showed a reduction in the average AMY1 copy number from healthy 
(mean= 8.86) to obese (mean= 8.11) breast cancer patients. AMY1-62 also showed a 
reduction in the average AMY1 copy number from healthy (mean= 9.69) to obese 
(mean= 8.06). Each assay provided evidence for an inverse correlation between AMY1 
copy number and obesity risk in breast cancer patients, although the difference in 
AMY1 copy number between healthy and obese breast cancer patients was only 
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statistically significant using the AMY1-62 primer probe assay (p= 0.02). Overall the 
two different AMY1 assays are supported by previous reports of a relationship between 
lower AMY1 copy number and susceptibility toward obesity (8, 139, 140). 
Germline AMY1 copy number from the breast cancer study cohort was also compared 
to other pathological features; ER (positive vs negative); PR (positive vs negative); 
HER2 (positive vs negative); and Grade (1&2 vs 3) (Supplementary Table 6.1). These 
comparisons indicated that patient germline AMY1 copy number was not significantly 
different between ER+ versus ER- (p= 0.67); PR+ versus PR- (p= 0.28); HER2+ versus 
HER2- (p= 0.76); and Grade 1-2 versus 3 (p= 0.15) breast tumours (AMY1-62 assay). 
Additional analysis of the association between BMI and pathological features of the 
patient’s breast tumours, indicated that there was no significant difference within the 
pathological characteristics of the breast tumours between obese and healthy patients 
(Supplementary Table 6.2).  
Overall, germline AMY1 copy number did not differ within clinically important breast 
tumour pathological features, but does show an inverse correlation with BMI in breast 
cancer patients.  
 
3.3.2 Comparing AMY1 Copy Number Determined using Quantitative PCR and 
Digital PCR 
The aim for this section was to determine if methodological technique plays a role in 
copy number determination. AMY1 copy number in germline DNA, determined using 
quantitative PCR (qPCR) and digital PCR, was compared between three breast cancer 
patients and one healthy control sample (Figure 3.2). qPCR results gave the three 
samples (patients 5, 8, 22) copy number estimates of 8.7, 15.3 and 6.4 copies 
respectively. Alternatively, digital PCR predicted the same three samples to have copy 
number estimates of 12.3, 15.6 and 7.6, respectively. The germline AMY1 copy number 
calculated by digital PCR was higher, compared to qPCR, for all three patient samples. 
The biggest difference in calculated copy number was patient Sample 5, with a 
difference of 3.6 copies, and the smallest difference was in Sample 8 with a difference 
of 0.3 copies. Digital PCR produced marginally higher AMY1 copy number numbers 
compared to qPCR (p= 0.51). 
39 
 
Figure 3.1 AMY1 copy number estimates for healthy (n= 27; pink) and obese (n= 28; grey) patients 
determined using quantitative PCR. Error bars represent the standard error of mean of each 
population. Two assays were used to determine sample copy number; Hs07226361_cn (AMY1-61) 
and Hs07226362_cn (AMY1-62). Only AMY1-62 showed significant difference between healthy 





Restriction digestion is a required process when using digital PCR to determine 
genomic copy number. When investigating the digested DNA samples (n=3) using 
qPCR, the resulting AMY1 copy numbers were more similar to the copy numbers 
calculated following digital PCR (p= 0.89), than between the undigested qPCR and 
digital PCR AMY1 copy numbers mentioned above. The comparison of digested and 
undigested patient DNA sample copy numbers (p= 0.56), determined when using 




Figure 3.2 AMY1 copy number determined using quantitative PCR (undigested and digested 




3.4 Discussion  
In the present study, it was confirmed that lower germline AMY1 copy number is 
































correlation between AMY1 copy number and BMI was observed in obese compared to 
healthy breast cancer patients. It was also established that both methodological process 
and the number of AMY1 duplicates per genome may influence the calling accuracy of 
germline AMY1 copy number in purified DNA samples from breast cancer patients. 
Using restriction digestion to individualise each AMY1 duplicate for copy number 
determination using quantitative PCR (qPCR) is not currently recognised as a necessary 
process, yet when applied, was seen to alter the calculated copy number in samples 
with lower range AMY1 duplication.  
The current analysis has confirmed the inverse correlation between germline AMY1 
copy number and risk toward accumulation of excess fat, initially reported by Falchi et 
al.(8). Additional studies investigating differing cohorts around the world have managed 
to replicate this reported inverse association(139, 140). Yet despite the supporting evidence 
for this inverse association, the underlying physiological and/or metabolic functions 
that explain the apparent fitness advantage linked to the increased duplication of AMY1 
copy number is yet to be identified. Researchers have confirmed that variation in AMY1 
copy number is positively correlated with dosage of AMY1 mRNA, salivary amylase 
protein and salivary amylase enzymatic activity rate(7, 137).  
Based on the current findings, it would be logical to expect high AMY1 copy number 
resulting in higher blood glucose levels, compared with low AMY1 copy number, after 
an intake of starch. Based on this, many studies have focused on the ability of variation 
in salivary amylase to manipulate the glycemic load experienced by subjects after the 
ingestion of starch rich meals. The glycemic load is an estimate of how much a 
particular food would increase a person’s blood glucose levels after consumption, in 
which lower GI foods are considered favourable to overall health. An informative in 
vivo study released starch samples straight into the small intestine, missing out the oral 
digestion process, and observed these subjects had substantially decreased starch 
digestion and glycemic load(145). Interestingly however, when assessed in subjects with 
either high or low salivary amylase copies and therefore high or low enzymatic 
concentration and activity rate, the opposite effect was observed. Subjects with low 
salivary amylase concentrations had substantially higher blood glucose levels following 
starch ingestion(138), which was attributable to low salivary amylase lessening the pre-
absorptive insulin release. Additionally, a clinical experiment inhibited the enzymatic 
activity of salivary amylase and therefore slowed down the digestion and absorption of 
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dietary starch and observed a reduced spike in blood glucose after a carbohydrate rich 
meal, favouring the expected response. However, also observed was a decrease in 
weight over a 12 week period of salivary amylase inhibition (on average, 2.9 kg), 
disputing the existing theory(146).  
It has been suggested that the functional link between salivary amylase and increased 
weight gain may be connected with food perception, in which increased and/or reduced 
breakdown of starch influences the perceived sensation of oral food texture and flavour. 
When increasing concentrations of the amylase enzyme were added to custards, 
subjects reported reduced “food creaminess”, “creamy mouth after sensations” and 
“flavour release”, all of which are believed to be favourably desired food qualities(147, 
148). These results perhaps suggest that reduced amylase dosage attributable to lower 
AMY1 copy number has the ability to positively influence one’s liking of starchy foods. 
Based on this it could be hypothesised that individuals with lower amylase copy 
number are likely experiencing enhanced desirable sensations during oral ingestion of 
starch, and thus perhaps strengthening the chances of augmented dietary starch 
ingestion, compared to those with higher germline AMY1 copy numbers. This theory 
would agree with the current study’s observation where, in breast cancer patients, 
increased function of salivary amylase is correlated with decreased BMI.  
The lack of validation for the functional link between salivary amylase dosage and 
increased BMI, despite the support for the inverse correlation, could be attributable to 
the variable study cohorts in which the inverse association has been investigated. 
Although the current study has observed a definite trend toward reduced AMY1 dosage 
in obese breast cancer patients, only one of the assays used in the analysis reported a 
significant inverse relationship. The current lack of significance is possibly supported 
by a recent paper noting they observed no association between dosage of AMY1 copy 
number and risk toward the accumulation of excess fat, in a large, multi-ethnic obese 
and lean cohort(142). They suggest that the inconsistency between their findings and 
what has been previously reported is due to their use of higher resolution techniques, 
such as droplet digital PCR, to determine amylase copy number. Yet, of the previous 
publications reporting an inverse association between AMY1 copy number and obesity, 
two utilised digital PCR to determine AMY1 copy number within subject DNA 
samples(139, 140). The current analysis comparing the use of qPCR and digital PCR to 
calculate AMY1 copy number in germline DNA samples of breast cancer patients 
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suggests that digital PCR is calling marginally higher copy numbers compared to 
qPCR. Furthermore, the current evaluation has also considered that the lack of genomic 
DNA restriction digestion, that is required for copy number calculations using digital 
PCR, may be influencing the copy numbers that are calculated using qPCR. Overall, 
the comparison of quantitative PCR and digital PCR suggests that the germline AMY1 
copy number determined for an individual may vary depending partially on the 
experimental techniques that are used. Although contradictory, the findings by Usher et 
al., validate the importance of investigating AMY1 copy number, and its association 
with obesity risk, in breast cancer patients. Based on their findings, it cannot be 
assumed that obesity will be associated with low amylase copy number in different 
study cohorts. 
A limitation of the current analysis comparing qPCR and digital PCR germline AMY1 
copy number determination is the small sample size being investigated (n=3). The 
differences seen during this analysis would need to be investigated in a much larger 
cohort of germline DNA samples if they were to be validated.  
The current study supports a novel inverse correlation between AMY1 copy number and 
increased BMI in breast cancer patients. This relationship may provide evidence for 
low AMY1 copy number as a risk factor toward breast cancer development, through its 
association with obesity, but this inverse correlation still requires further validation. 
Firstly, the inverse association would need to be validated in a large cohort case-control 
investigation, and secondly, the fundamental functional connection between low 
salivary amylase dosage and increased fat accumulation would not only need to be 
identified but also confirmed to be biologically active in obese breast cancer patients. 
One thing is for certain, this is just the beginning of the AMY1 copy number and obesity 




Chapter 4  
4 Obese Breast Tumour Gene Expression Analysis  
4.1 Introduction 
The exact mechanisms responsible for causing the strong link between obesity and 
breast cancer are yet to be identified, despite extensive research that has provided 
confirmation for the strong association between them.  
Currently, little research has been carried out surrounding the gene expression profiles 
of breast tumour genes in patients with differing BMI status, and only two studies have 
developed transcriptomic profiles for breast tumours from obese patients(118, 119). 
Creighton et al. compared breast tumour gene expression patterns (n=103) from normal 
(BMI < 25) and overweight (BMI = 25-30) patients to obese (BMI > 30) tumour 
transcript patterns, from which they derived 662 genes significantly differentially 
expressed in obese breast tumours(118). Similarly, Fuentes-Mattei et al. generated 
comparable transcriptomic data for oestrogen positive obese (BMI > 30) compared to 
non-obese (BMI < 30) breast tumours. They identified 112 genes, 62 that had 
significantly increased and 50 that had significantly decreased expression in obese 
compared to non-obese tumours (n=137)(119).  
Although these intriguing findings suggest a potentially important relationship between 
gene expression patterns during breast tumourigenesis and the obese phenotype, further 
research is required with a well characterised cohort of breast cancer cases. The current 
study hypothesises that obese breast cancers are associated with differential expression 





4.2 Experimental Design and Research Aims 
4.2.1 Identifying Candidate Genes 
To identify genes associated with breast tumours from obese women, two publically 
available microarray expression datasets from previous publications were 
interrogated(118, 119). The aim was to determine which genes differently regulated in 
obese breast tumours appear in both gene expression datasets (section 2.4).  
Genes shared between the two datasets were further investigated using The Cancer 
Genome Atlas (TCGA) online repository of gene expression data from 825 breast 
tumours(114). To determine which clinically important tumour phenotypes are associated 
with expression differences of these candidate genes, expression data were compared 
between clinically important breast tumour phenotypes (ER+ vs ER-, PR+ vs PR- and 
HER2+ vs HER2-).  
 
4.2.2 mRNA and Protein Expression Analysis of Candidate Genes  
This study analysed 40 post-menopausal fresh/frozen breast tumour samples collected 
from The Cancer Society Tissue Bank (n=18, BMI < 25; n=22, BMI > 30) (see Table 
2.1 for patient clinicopathological data). The tumour samples were homogenised, RNA 
was collected, purified and reverse transcribed into complementary DNA (cDNA). 
Finally, quantitative PCR (qPCR) was used to determine the level of candidate gene 
expression in the breast tumours (section 2.5.2). Candidate gene expression was 
compared between obese and healthy breast tumours, with the aim of determining if the 
level of expression differed between these two BMI groups. 
After RNA extraction, protein was also purified from 36 tumour homogenates. Protein 
expression levels of GRIA2 and DUSP4 were analysed using Western blotting to 
establish if the trend in GRIA2 and DUSP4 gene expression between the healthy and 






4.3.1 Identifying Candidate Genes : Bioinformatic Analysis of Previous 
Microarray Analyses  
Investigation of Creighton et al.’s(118) previous microarray dataset identified a total of 
91 differentially regulated genes determined by probe IDs. They were presented as fold 
change in obese relative to healthy weight patients with both oestrogen receptor 
positive and negative (ER+ and ER-) tumours (Supplementary Table 6.3). Fuentes-
Mattei et al.’s(119) dataset lists the top 110 most differentially regulated genes 
determined by probe IDs and presented as log ratio differences in obese compared to 
non-obese patients with ER+ breast tumours (supplementary Table 6.4).   
Initially, the probe IDs mapping to genes that were significantly differentially regulated 
were compared across the Creighton et al.(118) and Fuentes-Mattei et al.(119) datasets, to 
identify which probe IDs were appearing in both datasets. This analysis identified five 
different probe IDs, three mapping to GRIA2, DUSP4 and NR2F1 (205358_at; 
204014_at; 209505_at) and two mapping to ADH1B (209612_s_at; 209613_s_at). 
Overall, the four genes that intersected both datasets and were identified as commonly 
dysregulated in obese compared to healthy breast tumours were GRIA2, DUSP4, 
NR2F1 and ADH1B (Figure 4.1).  
Both microarray datasets report that GRIA2, DUSP4 and NR2F1 are significantly 
downregulated in obese breast tumours, however, the direction of regulation of ADH1B 
is controversial (Table 4.1). Creighton et al.(118) report ADH1B to be downregulated in 
obese tumours but Fuentes-Mattei et al.(119) suggest ADH1B was upregulated in breast 





Figure 4.1 Venn diagram of statistically differentially expressed genes shared between the 
Creighton et al.(118) and the Fuentes-Mattei et al.(119) breast tumour microarray expression datasets.  
 
 
Table 4.1 Differential expression data for the four genes reported to be significantly differentially 
expressed in breast tumours from obese women compared to healthy women by both Creighton et 
al.(118) (BMI < 25 vs BMI > 30) and Fuentes-Mattei et al.(119) (BMI < 30 vs BMI > 30).  
 Creighton et al. Fuentes-Mattei et al. 
Genes Fold Change (Log2) P-Value Fold Change (Log10) P-Value 
GRIA2 -2.39 0.0082 -0.31 <0.001 
DUSP4 -1.80 0.0108 -0.83 <0.001 
NR2F1 -1.40 0.0322 -0.31 0.004 




Based on their appearance in both microarray datasets these four significantly 
differentially regulated genes were selected to be further analysed as the candidate 
genes. 
GRIA2, DUSP4, NR2F1 and ADH1B 
Creighton et al.  Fuentes-Mattei et al. 
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Gene expression data from The Cancer Genome Atlas (TCGA)(114) (http://www.cbio- 
portal.org/) was utilised to perform an analysis of the candidate gene markers in a large 
cohort of breast cancer patients. TCGA provides extensive gene expression and 
clinicopathological data for breast cancer tumours derived from 825 patients, including 
breast tumour ER (oestrogen receptor), PR (progesterone receptor) and HER2 (ERBB2 
expression) status. BMI information for patient tumour data in TCGA has not been 
recorded, thus no comparison could be made between breast tumours from obese and 
non-obese patients. The change in regulation of the four common genes was compared 
between the 825 breast cancer tumours based on presence or absence of the clinical 
biomarkers ER, PR and HER2.  
Analysis suggests that candidate genes generally displayed significant differences in 
expression between ER(+/-), PR(+/-) and HER2(+/-) breast tumours. All genes showed 
statistically significant (p< 0.05) higher expression in ER+ breast tumours (Figure 4.2), 
while only NR2F1 was not highly statistically significant (p <0.001) in PR positive 
breast tumours (Figure 4.2 and 4.3). However, within the HER2 phenotype GRIA2 and 
ADH1B are on average more highly expressed in HER2+, NR2F1 more lowly 
expressed in HER2+, and DUSP4 indicated no difference between HER2(+/-) breast 










Figure 4.2 Boxplots showing the difference in regulation of GRIA2, DUSP4, NR2F1 and ADH1B 
between TCGA patients that have ER positive (n= 403) and ER negative (n= 118) breast cancer 
tumours. Error bars represent the standard error of the mean for each BMI cohort. *P-values < 0.05 













Figure 4.3 Boxplots showing the difference in regulation of GRIA2, DUSP4, NR2F1 and ADH1B 
between TCGA patients that have either PR positive (n= 341) or PR negative (n= 179) breast 
tumours. Error bars represent the standard error of the mean for each BMI cohort. ***P-values < 
0.001 are statistically significant differences in gene expression between PR positive and PR 













Figure 4.4 Boxplots showing the difference in regulation of GRIA2, DUSP4, NR2F1 and ADH1B 
between TCGA patients that have HER2 positive (n= 75) and HER2 negative (n= 433) breast cancer 
tumours. Error bars represent the standard error of the mean for each BMI cohort. *P-values < 0.05 
are statistically significant differences in gene expression between HER2 positive and HER2 





4.3.2 Candidate Gene Expression in Breast Tumours from Obese and Healthy 
Weight Women   
4.3.2.1 GRIA2, DUSP4, NR2F1 and ADH1B mRNA expression in obese 
breast tumours 
All four of the candidate genes (GRIA2, DUSP4, NR2F1   and ADH1B) exhibited 
decreased mean expression in obese relative to healthy weight breast tumours, although 
these differences were not statistically significant (Figure 4.5). The largest difference in 
expression was seen in ADH1B, expressing at least approximately 5X less in obese 
compared to healthy breast tumours. GRIA2 had the smallest difference in expression in 
obese relative to healthy tumours, with half the amount in obese tumours. The healthy 
cohort had greater variation in candidate gene expression, whereas the obese tumours 
had more tightly clustered candidate gene expression. The coefficient of variation for 
GRIA2, DUSP4, NR2F1 and ADH1B expression in the healthy group was 3.09, 2.36, 
1.45 and 3.28, respectively. Similarly, the coefficient of variation for GRIA2, DUSP4, 
NR2F1 and ADH1B expression for the obese group was 2.28, 0.98, 0.99 and 1.10, 
respectively. The increased variation in candidate gene expression within the healthy 
cohort may be explained by the unusually high expression of one influential tumour 
sample (Figure 4.6). The same influential tumour sample had unexpectedly high GRIA2 
and DUSP4 expression. Similarly, a second tumour sample was expressed at an 
unexpectedly high level for NR2F1 and ADH1B, influencing the analyses of these 
genes. Interestingly, when these influential points were removed from the analysis and 
fold change values re-calculated, the variation within the healthy cohort was 
substantially reduced across all four candidate genes (Supplementary Figure 6.4). 
However, the differences between the obese and healthy cohorts were still not 
statistically significant. The fold change in DUSP4, NR2F1 and ADH1B expression for 
the obese group relative to the healthy group was also reduced by 0.40, 0.14 and 0.52, 
respectively, but remained downregulated in tumours from obese women. In contrast, 
the difference in GRIA2 expression for obese relative to healthy tumours was increased, 
and was also reversed; GRIA2 was being upregulated in obese breast tumours. 
Nevertheless, the influential values were not removed from the final analysis, as they 
were real expression values for these breast tumour samples.  
Candidate gene expression was also compared within pathological features of the 
patients’ breast tumours (Table 4.2). The expression of GRIA2, DUSP4, NR2F1 and 
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ADH1B followed the same trends of expression between these pathological features as 
was seen in the analysis using TCGA data. However, only GRIA2 showed a statistically 
significant association with ER+/- and PR+/- tumours. Lastly, the pathological status 
(ER, PR and HER2) of the tumours was compared to the patients’ BMI (Table 4.3). 
There was no significant difference in the mean BMI scores between patients with ER, 





Figure 4.5 The relative expression in obese (BMI > 30; n= 22) compared to the healthy (BMI < 25; 
n= 18) breast tumour cohorts for GRIA2 (p= 0.52), DUSP4 (p= 0.27), NR2F1 (p= 0.12) and ADH1B 
(p= 0.29) expression. The healthy tumours are the pink bars and the obese the grey bars. The error 
























































































Figure 4.6 The difference in gene expression (target/reference), for GRIA2 (p= 0.52), DUSP4 (p= 
0.27), NR2F1 (p= 0.12) and ADH1B (p= 0.29) in breast tumours (n=40). The target/reference ratios 
are the level of target gene expression normalised to the reference gene (EFF1A1) in that sample. 
Each circle represents an individual tumour sample, the pink cluster the healthy weight tumours and 
the grey, tumours from obese patients. The errors bars are the standard error of the mean for each 






Table 4.2 Analysis of candidate gene expression within the pathological features of the patients’ 
















Fold Change1 0.01 0.005 270.194 
P-Value 0.047* 0.047* 0.054 
DUSP4 
Fold Change1 0.185 0.221 3.681 
P-Value 0.06 0.091 0.183 
NR2F1 
Fold Change1 0.433 0.394 0.979 
P-Value 0.066 0.051 0.960 
ADH1B 
Fold Change1 0.180 0.188 1.492 
P-Value 0.252 0.275 0.431 
1Difference in candidate gene expression in negative compared to positive breast tumours  





Table 4.3 Comparison of the patients BMI within the pathological features of the breast tumours. 
Pathological Feature    Sample Size  Average BMI P-value 
ER Status 
Negative 11 28.4 
0.96 
Positive  28 28.3 
PR Status 
Negative 13 28.8 
0.93 
Positive  25 28.6 
HER2 Status 
Negative 22 29.7 
0.88 




4.3.2.2 DUSP4 and GRIA2 protein expression in obese breast tumours 
GRIA2 and DUSP4 were chosen from the candidate genes as they have quality 
antibodies that are well validated, and are available for human sample analysis. 
Additionally, DUSP4 is well supported in the literature to be associated with breast 
cancer. The DUSP4 protein expression correlated with DUSP4 mRNA expression in 
obese compared to healthy breast tumours (Figure 4.7). Densitometry analysis of 
DUSP4 protein expression exhibited, on average, a trend toward lower levels of 
DUSP4 in obese (mean= 0.37) compared to healthy (mean= 1.60) breast tumours; 
however, this difference was not statistically significant (Figure 4.7 (B)). 
The healthy cohort of breast tumours displayed greater variation, than the obese group, 
in DUSP4 protein expression. When probed for β-actin (the loading control) tumour 
sample 1 belonging to a healthy weight patient consistently expressed β-actin at levels 
approximately 300x less than the average expression of β-actin in the healthy tumour 
cohort. However, the same breast tumour had DUSP4 levels that were only 10% lower 
than the average DUSP4 expression of this study cohort (Figure 4.8). Thus, after 
densitometry analysis normalising DUSP4 expression to its relative β-actin, sample 1 
had an atypically high level of DUSP4 expression, causing a significant increase in the 
standard error of the mean in the healthy weight group. Interestingly, sample 1 was not 
the same tumour specimen that was expressing unusually high levels of DUSP4 mRNA 
in the previous analysis (Figure 4.6); instead, sample 1 expressed relatively average 
levels of DUSP4 mRNA compared with the healthy tumour cohort. Thus, all of the 
tumour samples remained in the analysis of DUSP4 protein expression.  
Due to the low, barely detectable GRIA2 protein expression in the same tumour 
samples, expression data could not be derived for GRIA2 through Western blotting. 
Optimisation included increasing primary antibody concentration from 1/2000 to 1/500, 
increasing the total protein load from 10 µg to 40 µg per sample and re-wetting the 
membrane with methanol in case of accidental drying out during the transfer process. 
Despite making these changes to the original protocol, the GRIA2 bands were faint, and 























Figure 4.7 A) The average difference in gene expression (target/reference), for DUSP4, in breast 
tumours from healthy (n= 18, pink) and obese (n= 22, grey) women (p= 0.27). The target/reference 
ratios are the level of target gene expression normalised to the reference gene (EFF1A1) in that 
sample. Error bars are the standard errors of the mean.  B) The protein average expression of 
DUSP4 in obese (n= 20, grey) and healthy (n=16, pink) weight breast tumour samples (p= 0.25). 




































































 Figure 4.8 Representative Western blots of DUSP4 with 3 minute exposures and 10 µg of total 
protein loaded per well. A) Tumour samples: 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. Red arrow- Sample 1 
has low expression of β-actin and normal DUSP4 expression. B) Tumour samples: 12, 15, 16, 17, 
18, 19, 20, 21, 24, 25, and 7. Sample 7 was used as a positive control to normalise across gels.  
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4.4  Discussion 
The current analysis of candidate gene expression in breast tumours from obese women 
and women with a healthy weight determined that DUSP4 was trending towards 
downregulation in obese compared to healthy breast tumours, and this correlated with 
DUSP4 protein expression in these tumours. Similarly, this study revealed that GRIA2, 
NR2F1 and ADH1B mRNA showed a trend toward downregulation in obese breast 
tumours. However, no statistically significant differences were observed with mRNA 
and DUSP4 protein expression in the current study cohort of breast tumours from obese 
and healthy weight women. Despite using different techniques for resolving mRNA 
expression, the overall decrease observed for GRIA2, DUSP4, and NR2F1 in tumours 
from obese women is supported by the previous microarray analyses. Similarly, the 
lower expression levels of ADH1B in breast tumours from obese women agrees with 
the earlier of the two genetic signatures(118, 119). 
Initially, this chapter explored current gene expression profiles of obese breast tumours 
in order to identify and examine candidate genes that are differentially regulated in 
tumours derived from obese compared to healthy breast cancer patients. Considering 
that the underlying biological mechanisms responsible for the link between obesity and 
breast cancer are yet to be identified, it is surprising that only two previous analyses 
have reported transcriptomic profiles of obese breast tumours(118, 119). A comparison of 
datasets derived from each of these studies identified four obesity associated candidate 
genes (GRIA2, DUSP4, NR2F1 and ADH1B) that were significantly differentially 
expressed in breast tumours (Figure 4.1). The GRIA2 (glutamate receptor, ionotropic, 
AMPA 2) gene codes for one of four glutamate receptor subunits (GRIA1-4) 
collectively forming a ligand-activated cation channel predominantly found in the 
mammalian brain(149). The DUSP4 enzyme, encoded by DUSP4 (dual specificity 
protein phosphatase 4), is localised to the cell nucleus and inactivates ERK1, ERK2 and 
JNK via phosphorylation(150). NR2F1 (nuclear receptor subfamily 2, group F, member 
1), also known as COUP-TFI (COUP transcription factor 1), encodes a steroid hormone 
receptor protein, in which the targets of this transcriptional factor have not yet been 
fully identified(151). Lastly, the ADH1B enzyme, encoded by ADH1B (alcohol 
dehydrogenase 1B), functions with high activity for ethanol oxidation and plays a main 
role in the catabolism of ethanol(152).  
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GRIA2, DUSP4, NR2F1 and ADH1B are upregulated in ER+ and PR+ breast tumours, 
but show unique trends of up or downregulation within HER2+/- breast tumours 
(Figures 4.2-4.4). These results are somewhat supported by previous research that 
observed GRIA2 expression to be associated with breast cancer through its co-
clustering with the expression of ESR1 (oestrogen receptor 1) in primary invasive 
breast tumour biopsies, expressing at higher levels in ER+ breast tumours(116). 
However, other studies have not reported any statistical or molecular association 
between GRIA2 expression and the ER, PR and HER2 status of breast tumours. Overall 
this investigation suggests that GRIA2, DUSP2, NR2F1 and ADH1B may represent 
novel co-expressing ER, PR and/or HER2 related genes, but further investigation of 
their expression is required to determine whether these genes have the ability to aid in 
clinical applications.  
The current study has shown that downregulation of DUSP4 correlates with reduced 
levels of DUSP4 protein in obese breast tumours. Assuming that lower DUSP4 protein 
concentrations in the obese breast tumours are paralleled with a reduced rate in its 
enzymatic activity, it is reasonable to expect DUSP4 mRNA to be expressed at lower 
levels in obese breast tumours. DUSP4 inactivates ERK1, ERK2 and JNK via 
phosphorylation(150). Increased levels of JNK have been associated with the risk of 
obesity, obesity induced hyperinsulinemia, and more importantly, increased anti-
apoptotic signalling(153-155). Similarly, ERK1 and ERK2 are involved in a mitogen-
activated protein kinase (MAPK) signalling cascade that is significantly upregulated in 
many different human cancers in which signalling promotes cellular migration, 
survival, proliferation and cell cycle progression(155, 156). Additionally, highly aggressive 
basal-like breast cancers have been associated with a reduction in DUSP4 mRNA 
expression. Evidence suggests that deficiencies in DUSP4 regulate the resistance to 
anti-tumour chemotherapies in these aggressive breast tumour subtypes by promoting 
interleukin-6 and interleukin-8 expression to generate a cancer stem cell phenotype(150, 
157). Supplementary Figure 6.6 depicts a schematic of the DUSP4 pathway model 
proposed by Balko et al., in basal-like breast cancers(150). Based on this, I hypothesise 
that downregulation of DUSP4, observed in breast tumours from obese women, is 
analogous to that shown in basal-like breast cancers, where increasing levels of ERK1, 
ERK2 and JNK, promote cellular mitosis and supress stress induced apoptosis. Such a 
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molecular phenotype in breast tumours from obese patients may contribute to poorer 
prognosis and poorer treatment responses.  
Of all the candidate genes analysed in this study, DUSP4 is the only gene consistently 
recognised in the literature for its association with breast cancer. However, the 
literature surrounding the association of DUSP4 expression with breast tumourigenesis 
is still controversial. In support of the current study’s findings, some researchers have 
provided evidence for increases in DUSP4 acting in the suppression of tumour 
progression and metastasis(158-160), whereas opposing evidence suggests that higher 
DUSP4 expression is playing a role in promoting breast cancer growth and 
proliferation(161-163). These previous examinations of DUSP4 expression have 
investigated differences only between malignant and benign breast tissues, thus the 
current study is the first to directly measure DUSP4 mRNA in breast tumours from 
healthy and obese patients.  
Aside from evidence proposing that adipokines are involved in the upstream regulation 
influencing the development of the overall obesity associated genetic signature(119), 
there is no current evidence describing the biological systems causing DUSP4 to be 
uniquely downregulated in obese breast tumours. Investigation of the mechanisms 
responsible for lower DUSP4 expression in breast cancer could reveal cellular systems 
linking obesity and the initiation of more aggressive breast tumours. For breast tumours 
developing in obese patients, better understanding of these functional mechanisms may 
elucidate potential targets for future therapies that can counteract the trend toward 
obese breast tumour DUSP4 deficiency, observed in the current analysis. 
Research investigating expression levels of GRIA2 in different types of cancer cells, 
including liver, intestine, brain and uterus, has shown that downregulation of GRIA2 
both promotes and conversely supresses cancer cell replication(164-167), but only one 
study has provided evidence for an association between breast cancer and GRIA2 
expression(116). The current study showed that the trend toward lower GRIA2 expression 
in breast tumours from obese women was reversed when the single influential sample 
was removed from the analysis, suggesting that this trend is inconclusive (Figure 4.5, 
Supplementary Figure 6.4). This uncertainty could imply that the level of GRIA2 
expression in breast tumours is only associated with BMI by chance, or, that its link to 
obesity in previous genetic signatures(118, 119) is possibly due to its connection with 
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ESR1(116). The gene expression results from the current study suggest that GRIA2 was 
the only candidate gene significantly associated with ER status of the breast tumours 
(Table 4.2). This is supported by this previous link between GRIA2 and ESR1 
expression(116). Furthermore, the obese breast tumour genetic signature determined by 
Creighton et al. did not harbour ER, PR or any other oestrogen controlled genes, but 
did associate statistically with reduced ER levels(118). The literature surrounding the 
association between obesity and ER status in breast cancer is still controversial(168). 
This may explain why this study saw no association between BMI and the ER, PR and 
HER2 status of the breast tumours. 
Investigations of ER+ breast cancer cell lines have reported an up regulation of NR2F1 
to be involved in the progression of breast cancer. Increased NR2F1 expression during 
breast tumour development is suggested to modulate oestrogen signalling and thus is 
participating in enhancing tumour growth, invasion and hormone resistance(169, 170). 
This is contrary to observations from the current study, in that breast tumours from 
obese women, that could be expected to have more progressive cancers, were 
expressing lower levels of NR2F1 compared to tumours from healthy weight women. 
However, unlike the previous studies which showed NR2F1 expression in 
predominantly ER+ breast cancer cell lines, the current study analysed NR2F1 
expression in both ER+ and ER- breast tumours, making comparison across these 
studies difficult.  
The expression of ADH1B is not associated with the initiation or progression of breast 
cancer. On the other hand, the regulation of ADH1B, in another breast tissue (adipose), 
has been associated with risk factors strongly linked to breast cancer, such as obesity 
and insulin resistance(171).  
Although the previous microarray studies(118, 119), by Creighton et al. and Fuentes-
Mattei et al., analysed gene expression in similar sized cohorts of pre-treatment breast 
tumour biopsies, the obesity-signatures from these studies were derived from slightly 
different tumour cohort pathologies and comparisons. Creighton et al. analysed mRNA 
in both ER positive and negative (ER+/-) tumours, and compared gene expression 
patterns from healthy (BMI < 25) and overweight (BMI = 25-30) tumours combined, to 
obese (BMI > 30) tumours(118). In contrast, Fuentes-Mattei et al. analysed mRNA from 
ER+ breast tumours only, comparing gene expression patterns between healthy (BMI < 
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25) and obese (BMI > 30)(119). Despite these inter-study differences conceivably 
limiting the likelihood of seeing any gene overlap between the studies, comparison of 
the datasets derived from each of these studies identified four common genes (GRIA2, 
DUSP4, NR2F1 and ADH1B) differentially expressed in obese breast tumours.  
The current study used a relatively small sample size for both mRNA (n=40) and 
protein (n= 36) expression analysis. If the trend seen in this study, downregulation of 
expression in breast tumours from obese women, is valid then it is likely that with a 
larger cohort the trend would become significant. The smaller sample numbers used in 
this study make the results vulnerable to outliers influencing the statistical analyses. 
The exclusion of the influential values contributed toward less variation in the healthy 
cohort and a reversal in GRIA2 obese breast tumour expression (Supplementary Figure 
6.4). However, results obtained during this study were from assays carried out in 
triplicate, therefore, all of the observed expression data remained in the final analysis.  
It is well known that patient obesity is strongly associated with increasing the risk of 
breast cancer and developing more invasive and metastatic breast tumours, particularly 
in post-menopausal women(3, 4). Better understanding of the obese breast tumour 
transcriptome may help identify genes involved in the underlying mechanisms 
responsible for these links between obesity and breast cancer. The current study 
suggests that low GRIA2, DUSP4, NR2F1 and ADH1B expression in breast tumour 
biopsies may be related to patient obesity. However, these results are inconclusive, and 
further investigations with larger sample sizes would need to be done to better examine 





Obesity is a strong predictor for both increased prevalence and reduced survival rate in 
diagnosed breast cancer patients(3, 4). Yet despite the strong link between obesity and 
breast cancer, the precise underlying mechanisms responsible for such a strong 
association are yet to be identified. Therefore, the overall aim of this study was to 
explore the molecular links between obesity and breast cancer, in order to identify 
genes potentially influencing obesity associated breast cancer incidence and mortality. 
This study explored two different forms of genomic changes within 55 breast cancer 
patients. Initially, a form of germline alteration known as copy number variation (CNV) 
was investigated in 55 breast cancer patient blood samples. Following this, changes in 
the level of candidate gene expression from 40 overlapping breast tumour biopsies were 
explored. 
Germline alterations are commonly inherited changes, but can also be de novo 
mutations that arise during development. Advantageously, germline changes can be 
explored in human blood samples as they are evident in all cells throughout the body. 
The germline alteration of interest for the current analysis was a CNV at the AMY1 
locus, due to its proposed inversed relationship with obesity(8). The AMY1 locus 
(1p21.1) codes for the salivary α-amylase enzyme, the most abundant enzyme secreted 
from the salivary glands. Salivary α-amylase begins the oral digestion of large starch 
molecules, in which are large polymers of glucose monomers. Salivary amylase breaks 
apart these monomers via hydrolysis of the internal α-1,4 glycosidic bonds. The AMY1 
salivary amylase genes exhibit extensive CNV in the human genome ranging anywhere 
between 0 and 20 copies per individual. It has been suggested that selection pressure 
imposed on historical populations, by higher starch consumption, resulted in the 
evolution of greater AMY1 copy numbers compared to populations adapted to low 
starch diets that have evolved lower AMY1 copy numbers(7).  
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The aim of the first hypothesis was to identify whether germline AMY1 copy number 
has a molecular link with breast cancer through its association with obesity. To test this 
hypothesis, I investigated the association between AMY1 copy number and obesity in a 
cohort of well-characterised breast cancer patients, using quantitative PCR (qPCR). It 
was observed that low germline AMY1 copy number was significantly associated with 
increased BMI in breast cancer patients. These findings are consistent with the 
previously reported inverse association between obesity and low germline AMY1 copy 
number(8, 139, 140). The results from this investigation suggest that low AMY1 dosage 
could indirectly increase the risk of breast cancer, through promoting the development 
of an obese phenotype.  
Salivary amylase is responsible for dietary starch breakdown into simple sugar 
molecules, as preparation for further digestion in the stomach. Based on this 
information, I propose that after starch ingestion, people possessing low AMY1 copy 
number and therefore low amylase levels, would have lower and more prolonged blood 
glucose loads compared to individuals with higher amylase copy number (Figure 5.1). 
As blood glucose increases, so too do insulin concentrations in the blood, as insulin 
assists the entry of blood glucose into cells such as muscle(172). Hyperinsulinemia is the 
extended increase in blood insulin, due to prolonged escalations of glucose. For 
individuals with low AMY1 copy number ingesting starch rich diets, the prolonged 
elevation of blood glucose may be the physiological link to increased risk of obesity. 
Hyperinsulinemia mimics insulin resistance in the body and is commonly recognised as 
a symptom of obesity(73), however, the causal relationship between obesity and 
hyperinsulinemia remains to be resolved. It has been suggested that reducing 
circulating insulin may act as a preventative and/or treatment measure for mammalian 
obesity and its associated complications(173). Based on this information and the current 
study’s findings I hypothesise that low dosage of AMY1 linking to hyperinsulinemia 
could initiate a proliferative feedback loop in which hyperinsulinemia is instigated in 
developing obesity, and obesity then heightens insulin hypersecretion (Figure 5.2). 
Obesity remains a complex and heterogenic disease. The model of obesity that emerges 
as a result of low dosage of salivary amylase cannot be assumed to be the only model of 
obesity that may be responsible for causing the increased incidence and reduced 









Figure 5.1 This diagram represents this studies proposed bio-mechanism occurring when people 
possessing low AMY1 copy number, and therefore low amylase levels, ingest starch rich meals 
compared to people with high AMY1 copy number. People with lower AMY1 copy number (red line) 
would have lower and more prolonged blood glucose loads that take longer to return to base-line, 
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Figure 5.2 Flow diagram representing the proposed model linking low AMY1 copy number/dosage 
to the increased risk of obesity. After the ingestion of a starch rich meal, individuals with lower 
AMY1 copy number undergo an increase in blood glucose that is slower and more prolonged than 
people that have higher AMY1 copy number. This prolonged blood glucose is followed by elevation 
in blood insulin concentrations, in which prolonged increase in blood insulin mimics a condition 
known as hyperinsulinemia. The close link between obesity and hyperinsulinemia makes it hard to 
determine whether hyperinsulinemia causes obesity or obesity causes hyperinsulinemia, or both. In 
this model a proliferative feedback loop (red arrows) between hyperinsulinemia and obesity links 
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It is widely appreciated that sustained hyperinsulinemia is considered a possible 
mechanism involved in obesity associated breast tumour initiation and/or 
progression(109). However, the precise way in which obesity associated 
hyperinsulinemia influences breast tumourigenesis remains unclear. Two previous 
microarray analyses have identified obese breast tumour genetic signatures, in which 
many genes were being either up or downregulated in obese compared to healthy breast 
tumours(118, 119). Within these signatures there are specific genes that are differentially 
expressed in obese patient’s breast cancers. The expression of these genes could 
provide a molecular link between obesity and obesity inducing co-morbidities, such as 
hyperinsulinemia, with the development and growth of breast carcinogenesis. The 
second hypothesis tested in this study was that obese breast cancers are associated with 
differential expression of candidate genes. This study identified four candidate genes 
(GRIA2, DUSP4, NR2F1 and ADH1B), recognised to be commonly dysregulated in 
these previously established obese breast tumour transcriptomes(118, 119). When directly 
measuring the level of GRIA2, DUSP4, NR2F1 and ADH1B mRNA expression in 
breast cancer biopsy homogenates from obese and healthy women, these candidate 
genes showed a trend toward downregulation in obese compared to the healthy breast 
tumours, although this trend was not statistically significant. These results are 
consistent with the findings from the two previous microarray studies(118, 119). 
Furthermore, it was determined that DUSP4 protein was also expressed at lower levels 
in obese compared to healthy breast tumours. 
 
Previous transcriptomic analyses support the current study’s observed downregulation 
of DUSP4 in obese relative to healthy weight breast tumours(118, 119). Based on previous 
research and this study’s results it is hypothesised that low expression of DUSP4 in 
obese breast tumours may play a role in aggressive cell phenotypes through its 
interaction with downstream MAPK enzymes. However, the upstream molecular 
mechanisms responsible for the likely downregulation of DUSP4 within these obese 
patients have yet to be identified. Fuentes-Mattei et al.(119) suggest the obesity signature 
of ER+ breast tumours, in obese versus healthy weight patients, is most likely occurring 
as a result of upstream regulation by adipokines, insulin and IGF-I signalling. Low 
DUSP4 expression is one of the genes within the obese breast tumour transcriptional 
signature, and therefore it is possible that prolonged insulin hypersecretion is acting to 
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negatively regulate DUSP4 expression. This means that hyperinsulinemia may not only 
be increasing the risk of becoming obese, but also acting as a mechanism inducing 
tumour proliferation by causing DUSP4 to be downregulated in obese breast tumours. 
Thus, lower AMY1 copy number may cause prolonged insulin hypersecretion after 
ingestion of starch resulting in an upstream regulation and reduced DUSP4 expression.  
 
Low AMY1 copy number has been speculated to be increasing the risk of obesity 
through its ability to cause prolonged increases in blood insulin concentrations 
following the consumption of starch rich meals. There may be a link between AMY1 
copy number and ADH1B expression in obese breast cancer through their proposed 
associations with hyperinsulinemia. ADH1B was observed to be downregulated in 
obese breast tumour samples, supported by the transcriptomic examination carried out 
by Creighton et al.(118). A previous study has observed reduced ADH1B expression 
correlating strongly with hyperinsulinemia and obesity in adipose samples from obese 
relative to healthy weight subjects (according to BMI and waist circumference 
measures)(171). This suggests that a reduction in ADH1B expression in obese breast 
cancers could be involved in inducing a degree of hyperinsulinemia within these 
tumours, triggering mitosis and increased tumour cell survival.  
 
Lower germline copy number of AMY1 may also be associated with a subsequent 
downregulation in AMY1 mRNA within breast tumours of obese patients. Fuentes-
Mattei et al.(119) recognised AMY1 to be differentially regulated in ER+ breast tumour 
biopsies from obese relative to healthy weight patients (Supplementary Figure 6.4). 
Interestingly, AMY1 was downregulated in obese tumours, which is perhaps what 
would be expected if obese breast cancer patients have significantly lower germline 
AMY1 copy numbers. The lower expression of AMY1 within the tumour of obese breast 
cancer patients could be influencing tumour hyperinsulinemia and perhaps more 
aggressive breast carcinogenesis.  
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Overall, this study has investigated potential molecular links (germline and tumour) 
that may be influencing the obesity associated increased risk and development of breast 
cancer. Results from this study indicated that obese breast cancer patients have both 
significantly lower germline AMY1 copy number and tumours with a trend toward 
lower GRIA2, DUSP4, NR2F1 and ADH1B expression. The link between lower AMY1 
copy number and reduced expression of these candidate genes, in obese women, may 
interact through their association with patient hyperinsulinemia to increase the risk of 
breast tumourigenesis and contribute to a more agressive tumour phenotype. 
 
 
5.1 Future Research  
To better understand the potential genetic link between AMY1 and breast cancer, future 
research is required to investigate both the germline AMY1 copy number and AMY1 
mRNA expression levels in healthy and obese breast cancer patients. The level of 
AMY1 expression within a patient blood sample can be compared to their observed 
copy number status. These correlations have already been established in the saliva and 
blood of healthy subjects(137) but not in breast cancer patient blood samples. 
Additionally, to test whether low AMY1 copy number is linked with hyperinsulinemia, 
and therefore obesity, it will be important to measure AMY1 copy number and the 
degree of insulin resistance in obese and healthy breast cancer patients. These findings 
will determine whether there is a correlation between hyperinsulinemia and low AMY1 
copy number.  
The current study has found a trend toward downregulation of GRIA2, DUSP4, NR2F1 
and ADH1B in obese breast tumours, but these associations were non-significant. If this 
study were to be continued, a larger sample cohort of breast cancer patients/tumours 
would need to be investigated in order to validate the observed molecular associations 
between obesity and breast cancer.  
To better quantify the level of GRIA2, DUSP4, NR2F1 and ADH1B protein expression 
in tumours, other technologies such as ELISA (enzyme-linked immunosorbent assay) 
could be used as they provide a more quantitative approach relative to Western blotting. 
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The DUSP4 ELSIA results could also be compared back to the DUSP4 Western blots 
carried out in the current study. 
There is considerable evidence that dysregulation of DUSP4 is playing a role in the 
basal-like breast cancer aggressive phenotype(150). Whether the downregulation of 
DUSP4 is associated with aggressiveness in breast tumours from obese patients is yet to 
be identified. The current study has been the first to show a trend of lower DUSP4 
mRNA and protein expression, with increased BMI in breast cancers. Previous studies 
have established that downstream effects of reduced DUSP4 expression (ERK1, ERK2 
and JNK activation), are influencing breast cancer cells to become more aggressive. 
Therefore, it would be of value to analyse the expression of ERK1, ERK2 and JNK in 
the breast tumours from the current study. Lower levels of DUSP4 protein may be 
associated with increased quantities of DUSP4 downstream targets in obese breast 
tumours.  
A previous study suggests that that DUSP4 may being downregulated in some breast 
tumours due to copy number loss or epigenetic downregulation(150); however, the 
upstream regulation causing reduced DUSP4 expression is yet to be identified. Further 
research investigating the mechanisms responsible for DUSP4 downregulation in obese 
breast tumours would perhaps elucidate mechanisms tying in with obesity-associated 
patient hyperinsulinemia. The degree of insulin resistance of obese and healthy breast 
cancer patients could be compared to the level of DUSP4 expression within breast 
tumours. The influence of hyperinsulinemia on DUSP4 regulation may provide both a 
mechanistic and molecular link between obesity and breast cancer. This could provide a 
potential therapeutic breakthrough, significant for patients who have DUSP4 deficient 
obesity associated breast tumour phenotypes.  
 
 
5.2 Conclusion  
The overall aim for the current investigation was to explore potential molecular links 
between obesity and breast cancer, as the molecular and mechanistic basis of the 
obesity and breast cancer association still remains unclear. Furthermore, gene 
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expression changes in breast tumours from obese women remain poorly characterised. 
To my knowledge, this study has been the first to investigate the relationship of 
germline AMY1 copy number, and breast tumour GRIA2, DUSP4, NR2F1 and ADH1B 
gene expression in obese and healthy breast cancer patients.  
Results showed that obese breast cancer patients were associated with lower germline 
AMY1 copy number. Thus, due to a relationship with obesity low AMY1 copy number 
may be indirectly associated with a degree of genetic predisposition towards breast 
cancer. Additionally, the current study suggests that a trend toward lower GRIA2, 
DUSP4, NR2F1 and ADH1B expression, observed in breast cancers from obese 
women, may be suggestive of an obese patient phenotype. However, future research 
investigating a larger sample cohort would be needed to determine if such a relationship 
exists. 
Hyperinsulinemia is considered an important mechanism for risk and poor outcome in 
breast cancer. This study proposes molecular mechanisms including, low AMY1 copy 
number and negative regulation of DUSP4, that may underlie those links, and provide 











Supplementary Figure 6.1 Location of HindIII restriction digestion sites within the AMY1 target 
gene and RNase P (RPPH1) reference genes and the location of the primer/probe target sequences 














Supplementary Figure 6.2 A representative BSA standard curve and best fit line equation using 
BCA assay (0-1000 μg/mL). 
  







































Supplementary Figure 6.3 Schematic for the assembly of the transfer elements and the direction of 











Supplementary Table 6.1 Comparison of AMY1 copy number, for both Hs07226361_cn (AMY1-
61) and Hs07226362_cn (AMY1-62) primer/probe assays, to patient tumour pathological features. 
  AMY1-61 










ER Status Negative 13 8.24 0.51 
0.56 
 Positive 40 8.62 0.40 
PR Status Negative 16 7.86 0.47 
0.12 
 Positive 36 8.86 0.42 
HER2 Status Negative 36 8.23 0.37 
0.37 
 Positive 10 9.07 0.83 
Grade 1 & 2 17 9.12 0.60 
0.29 
 3 33 8.34 0.40 
 
  
  AMY1-62  











Negative 13 8.67 0.67 
0.67 
Positive 40 9.02 0.43 
PR Status 
Negative 16 8.42 0.57 
0.28 
Positive 36 9.21 0.45 
HER2 Status 
Negative 36 8.62 0.41 
0.76 
Positive 10 8.94 0.92 
Grade 
1 & 2 17 9.69 0.58 
0.15 












Supplementary Table 6.2 Comparison of patient tumour pathological features and patient BMI. 
Pathological Feature   Sample Size  Average BMI P-value 
ER Status 
Negative 11 29.17 
0.84 
Positive  38 29.74 
PR Status 
Negative 14 28.50 
0.70 
Positive  34 29.44 
HER2 Status 
Negative 33 30.36 
0.71 
Positive  9 31.51 
Grade 
1 and 2 17 29.75 
0.95 
3 33 29.59 
Histological Type 
IDC 29 30.11 
0.69 
Other 22 29.17 










Supplementary Table 6.3 List of genes statistically significantly (fold change and p value < 0.05) 
differentially expressed in breast tumours from obese (BMI >30) compared with healthy patients 
(BMI <25) from data generated by Creighton et al.(118). 
Gene Symbol Probe ID Fold Change P-Value 
GRIA2 205358_at -2.39 0.0082 
ADH1B 209612_s_at -2.3 0.0126 
AGTR1 205357_s_at -1.99 0.0227 
DUSP4 204014_at -1.8 0.0108 
GALNT7 218313_s_at -1.69 0.0096 
MEST 202016_at -1.68 0.0125 
SCUBE2 219197_s_at -1.68 0.0246 
FRY 204072_s_at -1.66 0.0017 
PRKAR2B 203680_at -1.65 0.008 
PLN 204939_s_at -1.6 0.0094 
SEMA3C 203789_s_at -1.59 0.0127 
TGFBR3 204731_at -1.58 0.0355 
GYG2 215695_s_at -1.57 0.032 
CCND1 208712_at -1.56 0.0214 
FMO2 211726_s_at -1.54 0.03 
IL6ST 212195_at -1.53 0.0075 
TFPI 213258_at -1.53 0.017 
ABAT 209459_s_at -1.52 0.0369 
RNASE4 213397_x_at -1.49 0.011 
TNFSF10 202688_at -1.48 0.024 
DUSP6 208892_s_at -1.48 0.0207 
FLRT3 219250_s_at -1.48 0.041 
ITM2A 202746_at -1.47 0.0463 
ITPR1 203710_at -1.47 0.0095 
TMEM47 209656_s_at -1.47 0.0122 
LRIG1 211596_s_at -1.47 0.003 
PCLO 213558_at -1.47 0.0038 
CLDN8 214598_at -1.46 0.0485 
BCL2 203685_at -1.45 0.0241 
KAL1 205206_at -1.45 0.0088 
BG251521 213156_at -1.45 0.0271 
CTBP2 201218_at -1.44 0.0004 
MAGI2 209737_at -1.43 0.0061 
GPD1L 212510_at -1.43 0.0023 
CDKN1C 213348_at -1.43 0.0165 
ENOSF1 213645_at -1.43 0.0006 
PLSCR4 218901_at -1.43 0.0182 
SPARCL1 200795_at -1.42 0.0416 
CYP1B1 202437_s_at -1.42 0.0381 
XIST 221728_x_at -1.42 0.0265 
NRIP1 202599_s_at -1.41 0.0307 
STS 203767_s_at -1.41 0.0209 
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ZNF91 206059_at -1.41 0.0032 
MEIS3P1 214077_x_at -1.41 0.0003 
HIST1H2AC 215071_s_at -1.41 0.0411 
BCL6 203140_at -1.4 0.0038 
209505_at (NR2F1) 209505_at -1.4 0.0322 
LIMCH1 212327_at -1.4 0.0211 
TNS1 221748_s_at -1.4 0.0491 
PODXL 201578_at -1.4 0.0062 
FAM13A 202973_x_at -1.39 0.034 
PER2 205251_at -1.39 0.000088 
ALG13 205583_s_at -1.39 0.0002 
ZDHHC17 212982_at -1.39 0.008 
ADI1 217761_at -1.39 0.0025 
HSD17B11 217989_at -1.39 0.0212 
CADPS2 219572_at -1.39 0.0081 
NBEA 221207_s_at -1.39 0.0127 
TMX4 201581_at -1.38 0.0169 
ACSL3 201661_s_at -1.38 0.014 
PKP4 201928_at -1.38 0.0002 
RHOBTB3 202976_s_at -1.38 0.025 
RB1 203132_at -1.38 0.0092 
PDZD2 209493_at -1.38 0.0329 
PION 213142_x_at -1.38 0.0113 
PGRMC2 213227_at -1.38 0.0069 
C1orf115 218546_at -1.38 0.0064 
RYBP 201845_s_at -1.37 0.0051 
PCM1 202174_s_at -1.37 0.0029 
KIF5C 203130_s_at -1.37 0.0334 
IRS2 209185_s_at -1.37 0.0171 
CACNA1D 210108_at -1.37 0.0268 
GPR116 212950_at -1.37 0.0275 
KIAA0485 214295_at -1.37 0.0115 
SLTM 217828_at -1.37 0.0026 
ADD3 201034_at -1.36 0.0416 
214753_at 214753_at -1.36 0.0026 
LZTFL1 218437_s_at -1.36 0.0075 
TRIM14 203148_s_at -1.35 0.0105 
TSC22D3 208763_s_at -1.35 0.0015 
NCOA1 209106_at -1.35 0.0002 
DOCK9 212538_at -1.35 0.0002 
ENO1 217294_s_at 1.36 0.0312 
S100G 207885_at 1.4 0.0333 
ARNTL2 220658_s_at 1.4 0.008 
NLRP2 221690_s_at 1.43 0.027 
CCL18 209924_at 1.46 0.0086 
KRT6B 213680_at 1.5 0.0415 
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MMP12 204580_at 1.56 0.0323 
S100A2 204268_at 1.58 0.0105 




Supplementary Table 6.4 List of genes statistically significantly (p≤0.01 and absolute value of log-
ratio > 0.1) differentially regulated in ER+ breast tumours in obese (BMI > 30) compared with non-
obese (BMI < 30) patients from data generated by Fuentes-Mattei et al.(119). 
Gene Symbol Probe ID Log ratio (Log10) P-Value 
PIP 206509_at -1.4353 <0.001 
AQP3 39248_at -1.2791 <0.001 
GJA1 201667_at -1.0564 0 
C8orf4 218541_s_at -1.0396 <0.001 
UGT2B28 211682_x_at -0.9668 <0.001 
MYBPC1 214087_s_at -0.964 <0.001 
NPY1R 205440_s_at -0.9324 <0.001 
CXCL13 205242_at -0.9132 <0.001 
SGK3 220038_at -0.8923 <0.001 
HSPA2 211538_s_at -0.8459 <0.001 
DUSP4 204014_at -0.8303 <0.001 
AREG 205239_at -0.735 <0.001 
PDLIM1 208690_s_at -0.7316 0.005 
PRSS23 202458_at -0.7164 0.004 
MUC1 207847_s_at -0.7116 0.009 
SERHL 214243_s_at -0.6772 <0.001 
CADM1 209031_at -0.5888 0.001 
SULF1 212344_at -0.5774 <0.001 
IGFBP5 211958_at -0.5225 0.007 
MSMB 207430_s_at -0.5198 <0.001 
EHF 219850_s_at -0.4399 0.003 
ANXA3 209369_at -0.4304 0.003 
SLC26A3 206143_at -0.4272 <0.001 
MMP10 205680_at -0.3848 <0.001 
FKBP5 204560_at -0.3581 <0.001 
IGHM 211634_x_at -0.3544 0.008 
SLC1A1 206396_at -0.353 <0.001 
TSPAN8 203824_at -0.3404 <0.001 
CITED1 207144_s_at -0.334 0.002 
PGR 208305_at -0.3336 <0.001 
RLN2 214519_s_at -0.3178 0.001 
GRIA2 205358_at -0.3115 <0.001 
NR2F1 209505_at -0.3106 0.004 
TFPI2 209277_at -0.3104 <0.001 
COL5A1 212489_at -0.3099 0.008 
CRISP3 207802_at -0.3012 <0.001 
IL20RA 219115_s_at -0.292 0.003 
SMARCA1 215294_s_at -0.2729 0.005 
NDP 206022_at -0.2659 0.004 
NPY5R 207400_at -0.2598 0.006 
GLRB 205280_at -0.2592 <0.001 
DLX2 207147_at -0.2522 <0.001 
PLCL1 205934_at -0.2443 0.002 
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AMY1A 208498_s_at -0.2336 <0.001 
MSLN 204885_s_at -0.227 <0.001 
FLJ11184 218513_at -0.216 <0.001 
FAM5C 217562_at -0.2126 <0.001 
UGT2B4 206505_at -0.1888 <0.001 
EREG 205767_at -0.1695 0.002 
IL33 209821_at 0.1552 0.008 
ATRNL1 213745_at 0.2 <0.001 
C11orf30 219012_s_at 0.208 0.004 
HBZ 206647_at 0.2222 0.007 
ALB 214842_s_at 0.2371 <0.001 
PEG3 209243_s_at 0.2394 0.001 
ITSN1 209298_s_at 0.2481 <0.001 
PIR 207469_s_at 0.2636 0.008 
CDSN 206193_s_at 0.2821 <0.001 
GSTT2 205439_at 0.2857 <0.001 
TIMP4 206243_at 0.2898 <0.001 
PCOLCE2 219295_s_at 0.2914 <0.001 
FHL1 201539_s_at 0.2978 <0.001 
MRC1 204438_at 0.3005 0.002 
IL8 211506_s_at 0.3015 <0.001 
DPT 213068_at 0.3045 0.001 
TRIM58 215047_at 0.3177 <0.001 
AFP 204694_at 0.3256 <0.001 
TF 203400_s_at 0.3302 <0.001 
CAV2 203323_at 0.3331 0.002 
RSF1 218166_s_at 0.3337 <0.001 
CLEC3B 205200_at 0.3466 <0.001 
AOC3 204894_s_at 0.3483 <0.001 
CHRDL1 209763_at 0.3489 0.0002 
CRABP1 205350_at 0.389 <0.001 
CP 204846_at 0.4028 0.001 
LBP 214461_at 0.412 <0.001 
ASCL1 209987_s_at 0.4495 <0.001 
TWIST1 213943_at 0.4551 <0.001 
RBP4 219140_s_at 0.4764 <0.001 
CD36 206488_s_at 0.4912 0.005 
ADH1B 209612_s_at 0.5118 <0.001 
LEP 207092_at 0.5158 <0.001 
ACOX2 205364_at 0.5172 0.002 
GRB14 206204_at 0.5212 <0.001 
CAV1 212097_at 0.526 0.002 
TOP2A 201292_at 0.5498 0.003 
PLOD2 202620_s_at 0.5637 0.002 
TSKU 218245_at 0.5767 0.001 
CLSTN2 219414_at 0.5877 <0.001 
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ADIPOQ 207175_at 0.6023 <0.001 
LPL 203548_s_at 0.6368 <0.001 
GPX3 201348_at 0.6369 <0.001 
PPBP 214146_s_at 0.6429 <0.001 
FABP5 202345_s_at 0.6529 <0.001 
SAA1 208607_s_at 0.6929 <0.001 
KCNK1 204679_at 0.6946 0.003 
AMIGO2 222108_at 0.6981 0.003 
PLIN 205913_at 0.7004 <0.001 
AKR1C3 209160_at 0.7246 <0.001 
G0S2 213524_s_at 0.7461 <0.001 
HBG1 204848_x_at 0.7619 0.002 
CFD 205382_s_at 0.7621 <0.001 
HBG2 204419_x_at 0.7872 0.001 
S100A8 202917_s_at 0.7919 <0.001 
HBD 206834_at 0.855 <0.001 
AKR1C1 204151_x_at 0.8679 <0.001 
AKR1C2 209699_x_at 0.8686 <0.001 
FABP4 203980_at 0.9573 <0.001 
SNCA 204466_s_at 0.9795 <0.001 











Supplementary Figure 6.4 The relative expression of the obese (BMI > 30; n= 22) compared to the 
healthy (BMI < 25; n= 17) breast tumour cohorts for GRIA2 (p= 0.47), DUSP4 (p= 0.60), NR2F1 
(p= 0.26) and ADH1B (p= 0.35) with the influential data points removed. The healthy tumours are 



































































































Supplementary Figure 6.5 Representative Western blot for GRIA2 with a 15 minute exposure and 
loading 40 µg of total protein per well. Tumour Samples: positive control, 12, 15, 17, 18, 19, 20, 21, 
24 and 25. 
  














Supplementary Figure 6.6 The proposed pathway model for the function of DUSP4 in basal-like 
breast cancers.  
Schematic taken from: Balko JM, Schwarz LJ, Bhola NE, Kurupi R, Owens P, Miller TW, et al. 
Activation of MAPK Pathways due to DUSP4 Loss Promotes Cancer Stem Cell-like Phenotypes in 
Basal-like Breast Cancer. Cancer research. 2013;73(20):6346-58.(150). Reprinted with permission 
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